A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02020889

Enrollment

136

Registered

2013-12-25

Start date

2014-02-05

Completion date

2016-09-05

Last updated

2018-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Churg-Strauss Syndrome

Keywords

eosinophils, SB 240563, Churg-Strauss Syndrome, quality of life, mepolizumab, safety, biomarkers, efficacy, corticosteroids, Eosinophilic granulomatosis with polyangiitis

Brief summary

The purpose of this randomized, double-blind study is to investigate the efficacy and safety of mepolizumab (300 milligram \[mg\] administered subcutaneously \[SC\] every 4 weeks) compared with placebo over a 52-week study treatment period in subjects with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care therapy including background corticosteroid therapy with or without immunosuppressive therapy. During the treatment period, in accordance with standard of care, corticosteroid dose will be tapered. The key outcomes in the study focus on evaluation of clinical remission, defined as Birmingham Vasculitis Activity Score (BVAS)=0 with a corticosteroid dose of \<=4 mg/day prednisolone/prednisone, reduction in disease relapse and reduction in corticosteroid requirement.

Interventions

BIOLOGICALMepolizumab

Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.

DRUGPlacebo

Placebo will be available as 0.9% sodium chloride

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials. * Age and gender: Male or female subjects age 18 years or older. * EGPA diagnosis: subjects who have been diagnosed with EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia (\>1.0x10\^9/Liter and/or \>10% of leucocytes) plus at least two of the following additional features of EGPA; a biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation; neuropathy, mono or poly (motor deficit or nerve conduction abnormality); pulmonary infiltrates, non-fixed; sino-nasal abnormality; cardiomyopathy (established by echocardiography or Magnetic Resonance Imaging); glomerulonephritis (haematuria, red cell casts, proteinuria); alveolar haemorrhage (by bronchoalveolar lavage); palpable purpura; anti neutrophil cytoplasmic anti-body (ANCA) positive (Myeloperoxidase or proteinease 3). * History of relapsing OR refractory disease defined as: Relapsing disease: Subject must have a past history of at least one confirmed EGPA relapse (i.e., requiring increase in oral corticosteroids (OCS) dose, initiation/increased dose of immunosuppressive therapy or hospitalisation) within the past 2 years which occurred at least 12 weeks prior to Screening (Visit 1) whilst receiving a dose of prednisolone (or equivalent) of \>=7.5 milligram per day (mg/day). Refractory disease: Either: Failure to attain remission (BVAS=0 and OCS dose \<=7.5 mg/day prednisolone or equivalent) within the last 6 months following induction treatment with a standard regimen, administered for at least 3 months. Note: a) Subjects who have received a cyclophosphamide (CYC) induction regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3 weeks after the last dose of pulsed intravenous CYC prior to Baseline (Visit 2), if their total white blood cells (WBC) is \>=4x10\^9/Liter (tested at the local laboratory, if necessary) prior to randomisation. b) Subjects who have received a methotrexate, azathioprine, or mycophenolate mofetil induction regimen may be included if on a stable dose for at least 4 weeks prior to Baseline (Visit 2). c) Subjects who have received an induction regimen comprising corticosteroids alone may be included only if they have failed to attain remission after 3 months of treatment AND the corticosteroid dose is \>=15 mg/day prednisolone or equivalent for the 4 weeks prior to Baseline (Visit 2). Or: Within 6 months prior to Screening (Visit 1), recurrence of symptoms of EGPA (not necessarily meeting the protocol definition of relapse) whilst tapering OCS, occurring at any dose level \>=7.5 mg/day prednisolone or equivalent. * Corticosteroid therapy: Subject must be on a stable dose of oral prednisolone or prednisone of \>=7.5 mg/day (but not \>50 mg/day) for at least 4 weeks prior to Baseline (Visit 2). * Immunosuppressive therapy: If receiving immunosuppressive therapy (excluding cyclophosphamide) the dosage must be stable for the 4 weeks prior to Baseline (Visit 2) and during the study (dose reductions for safety reasons will be permitted). * ECG measurements: QTc(F)\<450 msec or QTc(F)\<480 msec for patients with bundle branch block. The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual overread. For subject eligibility and withdrawal decisions, QTcFwill be used. For purposes of data analysis, QTcF will be used as primary though data using both correction formulas will be collected and analysed. The QTc should be based on single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period. * Female subjects: To be eligible for entry into the study, females of childbearing potential (FCBP) must commit to consistent and correct use of an acceptable method of birth control (as discussed in the protocol) beginning with consent, for the duration of the trial and for 4 months after the last study drug administration. * French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. * Liver Function Tests: obtained at Screening (Visit 1): ALT\<2x ULN (upper limit of normal) or if subject is on background methotrexate or azathioprine \<3x ULN; AST\<2x ULN or if subject is on background methotrexate or azathioprine \<3x ULN; Alkaline Phosphatase ≤2.0x ULN;Bilirubin ≤ 1.5x ULN (isolated bilirubin\>1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)

Exclusion criteria

* GPA or MPA: Diagnosed with granulomatosis with polyangiitis (GPA; previously known as Wegener's granulomatosis) or microscopic polyangiitis (MPA). * Organ-threatening EGPA: Organ-threatening EGPA as per European league against rheumatism (EULAR) criteria, i.e., organ failure due to active vasculitis, creatinine \>5.8 gram per deciliter (g/dL) (\>513 micromole per liter \[µmol/L\]) within 3 months prior to Screening (Visit 1). * Life-threatening EGPA: Imminently life-threatening EGPA disease defined as any of the following within 3 months prior to Screening (Visit 1); Intensive care required; Severe alveolar haemorrhage or haemoptysis requiring transfusion or ventilation or haemoglobin \< 8 gram per liter (g/dL) (\<80 g/L) or drop in haemoglobin \> 2 g/dL (\>20 g/L) over a 48 hour period due to alveolar haemorrhage; Rapidly progressive glomerulonephritis (RPGN) with creatinine \> 2.5 milligram per deciliter (mg/dL) (\>221 µmol/L) or rise in creatinine \> 2 mg/dL (\>177 µmol/L) over a 48 hour period; Severe gastrointestinal (GI) involvement, e.g., gangrene, bleeding requiring surgery; Severe central nervous system (CNS) involvement; Severe cardiac involvement, e.g., life-threatening arrhythmia, cardiac failure: ejection fraction \< 20%, New York Heart Association Class III/IV (as discussed in protocol), acute myocardial infarction. * Malignancy: A current malignancy or previous history of cancer in remission for less than 12 months prior screening (Subjects that had localized carcinoma (i.e., basal or squamous cell) of the skin which was resected for cure will not be excluded). * Liver disease: Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice), cirrhosis, and known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * Cardiovascular: Subjects who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment including but not limited to: Known ejection fraction of \<30%, OR Severe heart failure that meets New York Heart Association Class IV (as discussed in protocol), OR Hospitalised in the 12 months prior to Visit 1 for severe heart failure meeting New York Heart Association Class III (as discussed in protocol), OR Angina diagnosed less than 3 months prior to or at Visit 1 (Screening). * Other concurrent medical conditions: Subjects who have known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory or any other system abnormalities that are not associated with EGPA and are uncontrolled with standard treatment. * Infectious disease: Chronic or ongoing active infectious disease requiring systemic treatment. * Parasitic infection: Subjects with a parasitic infestation within 6 months prior to Screening (Visit 1). * Hepatitis status: Diagnosis of chronic hepatitis B, as evidenced by positive Hepatitis B surface antigen (HBsAg) at Screening (Visit 1). Japan only: Subjects positive for HBsAg , antibodies to HBsAg, i.e., HBsAb, or Hepatitis B core antigen, i.e., HBcAb, at Screening (Visit 1). Note: Subjects with antibodies to HBsAg, i.e., HBsAb positive, only (i.e., negative for HBsAg and HBcAb) with a history of hepatitis B vaccination can be included. * HIV: Subjects with a known human immunodeficiency virus infection. * Hypersensitivity: Subjects with a known allergy or intolerance to a monoclonal antibody or biologic therapy. * Previous mepolizumab: Subjects who have previously received mepolizumab within a 1 year period prior to Screening (Visit 1). * Prohibited medications: Subjects receiving any of the following: OCS: Subject requires an oral corticosteroid dose of \>50 mg/day prednisolone/prednisone in the 4-week period prior to Baseline (Visit 2); Intravenous or SC corticosteroids in the 4-week period prior to Baseline (Visit 2); Omalizumab within 130 days prior to Screening (Visit 1); Cyclophosphamide: oral CYC within 2 weeks prior to Baseline (Visit 2) and IV CYC within 3 weeks prior to Baseline (Visit 2), if their total WBC is \>=4x10\^9/Liter (measured using the local laboratory if necessary); Rituximab within 12 months prior to Screening (Visit 1); in addition, the subject must have shown recovery of peripheral B-cell count to within the normal range; IV or SC immunoglobulin within 6 months prior to Screening (Visit 1); Interferon-α within 6 months prior to Screening (Visit 1); Anti-TNF therapy within 12 weeks prior to Screening (Visit 1); Anti-CD52 (alemtuzumab) within 6 months prior to Screening (Visit 1). * Other laboratory parameter exclusions: Creatinine \> 2.5 mg/dL (221 µmol/L); WBC \< 4 x10\^9/Liter, Platelet count \<120,000/millimetre cube (mm\^3), Haemoglobin \<8 g/dL (\<80 g/L) * Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation. * Alcohol/substance abuse: A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to Screening (Visit 1). * Other investigational product: Subjects who have received treatment with an investigational drug within the past 30 days or 5 terminal phase half-lives of the drug whichever is longer, prior to Screening (Visit 1) (this also includes investigational formulations of marketed products). * Other clinical study: Subject is currently participating in any other interventional clinical study. * Adherence: Subjects who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations. * French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives (whichever is longer).

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants in Each Category of Accrued Duration of Remission	Up to Week 52	Total accrued duration of remission is the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose \<=4 mg/day over the 52 week study treatment period was reported. The accrued duration was categorized into zero, \>0 to \<12 weeks, 12 to \<24 weeks, 24 to \<36 weeks and \>=36 weeks. Statistical analysis was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. Intent-to-Treat (ITT) Population was used for the analysis and was defined as all participants who were randomized and received at least one dose of trial medication. Randomized participants were assumed to have received study treatment unless definitive evidence to the contrary exists. The odds ratio for treatment difference and associated probability (p)-value and 95 percent confidence interval (CI) were calculated.
Number of Participants Who Are in Remission at 36 and 48 Weeks	Week 36 and Week 48	The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone \<=4 mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Secondary

Measure	Time frame	Description
Time to First EGPA Relapse	Up to Week 52	EGPA relapse was defined as worsening or persistence of active disease since the last visit characterized by active vasculitis or active asthma symptoms and/or signs with a corresponding worsening in Asthma Control Questionnaire-6 (ACQ-6) score or active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions warranting: i) an increased dose of OCS therapy (or other systemic corticosteroid therapy) to \>4 mg/day prednisolone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalization related to EGPA worsening. Participants who completed study, or withdrawn prematurely from the study without experiencing the event were censored. The number of participants with at least one EGPA relapse during the planned study treatment period are presented.
Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	Week 48 and Week52	The number of participants with an average daily prednisolone/prednisone dose during the last 4 weeks of the Study Treatment Period (48 through 52) was calculated. The average dose was categorized into zero, \>0 to \<=4.0mg, \>4.0 to \<=7.5mg and \>7.5mg. The statistical analysis was performed using a proportional odds regression model with Baseline covariates of treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region and the comparison between treatment groups was presented as an odds ratio, p-value and 95 percent CI.
Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	Up to Week 52	The number of participants who achieved remission (i.e., BVAS=0 and prednisolone/prednisone\<=4 mg/day) within the first 24 weeks and remain in remission for the remainder of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.
Number of Participants in Each Category of Accrued Duration of Remission	Up to Week 52	Total accrued duration of remission, i.e., the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose \<=7.5mg/day over the 52 week study treatment period was reported. BVAS is a validated, clinician-completed tool used for the comprehensive multisystem clinical assessment of disease activity in systemic vasculitis. The duration was categorized into zero, \>0 to \<12 weeks, 12 to \<24 weeks, 24 to \<36 weeks and \>=36 weeks. Statistical analysis was performed on ITT Population and was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.
Number of Participants Who Are in Remission at 36 and 48 Weeks	Week 36 and Week 48	The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone \<=7.5mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.
Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	Up to Week 52	The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone \<=7.5mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.
Number of Participants With Local and Systemic Adverse Events (AEs)	Up to Week 52	An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs including systemic allergic and non-allergic reactions as well as local site injection-related reactions were counted throughout treatment phase and follow up phase. Systemic allergic reactions included Facial paralysis, flushing, hypersensitivity and rash pruritic. Injection related reactions were considered as systemic non-allergic reactions. Local site reactions included injection site bruising, erythema, pain and reaction. The analysis was performed on Safety Population which comprised of all participants who receive at least one dose of study treatment.
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in ALT, Alk.phosph., AST, creatinine kinase, GGT and lactate dehydro values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in albumin and protein levels values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in direct, indirect and total bilirubin and creatinine values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in calcium, chloride, cholesterol, glucose, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, phosphorus, potassium, sodium, urea nitrogen and very low density lipoprotein (VLDL) cholesterol values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured. NA indicates that data were not available.
Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in troponin values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelet values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in MCHC and hemoglobin values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in MCV values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in MCH values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Hematology Parameters of Erythrocytes Levels	Baseline and up to Week 60	Blood samples were collected to evaluate change from Baseline in erythrocytes values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Number of Participants With Anti-Mepolizumab Antibodies	Up to Week 60	Blood samples were collected for the determination of anti-Mepolizumab antibodies. Participants who showed presence of anti-Mepolizumab antibody were termed as 'positive' and those who did not have anti-Mepolizumab antibody in blood sample were termed as 'negative'. Participants who did not have a positive ADA assay prior to the first dose of investigational product were included in the analysis.
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	Baseline up to Week 60	SBP and DBP were measured from Baseline throughout follow-up (till Week 60) before injection with the participant sitting, having rested in this position for at least 5 minutes before reading. The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Pulse Rate	Baseline and up to Week 60	Pulse rate was measured from Baseline throughout follow-up (till Week 60) before injection with the participant sitting, having rested in this position for at least 5 minutes before reading. The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Change From Baseline in Body Temperature	Baseline and up to Week 60	Body temperature was measured from Baseline throughout follow-up (till Week 60). The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. The analysis was performed on Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	Baseline and up to Week 60	Single measurements of 12-lead electrocardiogram (ECGs) were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Mean change from Baseline in QTcF and QTcB values were measured. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Maximum Change From Baseline in QTcF and QTcB Values	Baseline and up to Week 60	Single measurements of 12-lead ECGs were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Maximum change from Baseline in QTcF and QTcB values were measured.

Countries

Belgium, Canada, France, Germany, Italy, Japan, Spain, United Kingdom, United States

Participant flow

Recruitment details

Eligible participants at screening and run-in visit, entered a 52 week study treatment phase followed by 8-week follow-up phase. The total duration for the study participation was approximately 64 weeks.

Pre-assignment details

A total of 151 participants with a history of relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) were screened, out of which 4 were screen failures and 11 were run-in failures. 136 participants completed run-in period and received Mepolizumab 300 milligram (mg) or placebo in a randomized manner in the treatment phase.

Participants by arm

Arm	Count
Placebo Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	68
Mepolizumab 300mg Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.	68
Total	136

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Adverse Event	0	1
Overall Study	Lack of Efficacy	1	0
Overall Study	Lost to Follow-up	1	0
Overall Study	Physician Decision	2	0
Overall Study	Withdrawal by Subject	3	2

Baseline characteristics

Characteristic	Mepolizumab 300mg	Total	Placebo
Age, Continuous	48.7 Years STANDARD_DEVIATION 12.39	48.5 Years STANDARD_DEVIATION 13.34	48.2 Years STANDARD_DEVIATION 14.32
Race/Ethnicity, Customized Race customized American Indian or Alaskan Native	1 Participants	1 Participants	0 Participants
Race/Ethnicity, Customized Race customized Asian - Japanese Heritage	3 Participants	6 Participants	3 Participants
Race/Ethnicity, Customized Race customized Asian - South East Asian Heritage	0 Participants	2 Participants	2 Participants
Race/Ethnicity, Customized Race customized Mixed Race	0 Participants	2 Participants	2 Participants
Race/Ethnicity, Customized Race customized White - Arabic/North African Heritage	2 Participants	2 Participants	0 Participants
Race/Ethnicity, Customized Race customized White - White/Caucasian/European Heritage	62 Participants	123 Participants	61 Participants
Sex: Female, Male Female	42 Participants	80 Participants	38 Participants
Sex: Female, Male Male	26 Participants	56 Participants	30 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 68	1 / 68
other Total, other adverse events	61 / 68	65 / 68
serious Total, serious adverse events	18 / 68	12 / 68

Outcome results

Primary

Number of Participants in Each Category of Accrued Duration of Remission

Total accrued duration of remission is the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose \<=4 mg/day over the 52 week study treatment period was reported. The accrued duration was categorized into zero, \>0 to \<12 weeks, 12 to \<24 weeks, 24 to \<36 weeks and \>=36 weeks. Statistical analysis was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. Intent-to-Treat (ITT) Population was used for the analysis and was defined as all participants who were randomized and received at least one dose of trial medication. Randomized participants were assumed to have received study treatment unless definitive evidence to the contrary exists. The odds ratio for treatment difference and associated probability (p)-value and 95 percent confidence interval (CI) were calculated.

Time frame: Up to Week 52

Population: ITT Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	>0 to <12 weeks	8 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	24 to <36 weeks	0 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	12 to <24 weeks	3 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	>=36 weeks	2 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	Zero	55 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	>=36 weeks	9 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	Zero	32 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	>0 to <12 weeks	8 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	12 to <24 weeks	9 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	24 to <36 weeks	10 Participants

p-value: <0.00195% CI: [2.68, 13.03]Proportional odds regression model

Primary

Number of Participants Who Are in Remission at 36 and 48 Weeks

The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone \<=4 mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Time frame: Week 36 and Week 48

Population: ITT Population

Arm	Measure	Value (NUMBER)
Placebo	Number of Participants Who Are in Remission at 36 and 48 Weeks	2 Participants
Mepolizumab 300mg	Number of Participants Who Are in Remission at 36 and 48 Weeks	22 Participants

p-value: <0.00195% CI: [3.61, 77.56]Regression, Logistic

Secondary

Change From Baseline in Body Temperature

Body temperature was measured from Baseline throughout follow-up (till Week 60). The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. The analysis was performed on Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Body Temperature	Absolute Baseline; n= 68, 68	36.52 Degree celsius	Standard Deviation 0.385
Placebo	Change From Baseline in Body Temperature	Week 4; n= 68, 68	0.05 Degree celsius	Standard Deviation 0.439
Placebo	Change From Baseline in Body Temperature	Week 8; n= 67,68	-0.01 Degree celsius	Standard Deviation 0.379
Placebo	Change From Baseline in Body Temperature	Week 12; n= 66, 68	0.05 Degree celsius	Standard Deviation 0.41
Placebo	Change From Baseline in Body Temperature	Week 16; n= 64, 68	-0.01 Degree celsius	Standard Deviation 0.421
Placebo	Change From Baseline in Body Temperature	Week 20; n= 63, 68	-0.08 Degree celsius	Standard Deviation 0.351
Placebo	Change From Baseline in Body Temperature	Week 24; n= 62, 67	-0.06 Degree celsius	Standard Deviation 0.449
Placebo	Change From Baseline in Body Temperature	Week 28; n= 63, 67	-0.06 Degree celsius	Standard Deviation 0.499
Placebo	Change From Baseline in Body Temperature	Week 32; n= 62, 67	-0.09 Degree celsius	Standard Deviation 0.392
Placebo	Change From Baseline in Body Temperature	Week 36; n= 62, 67	-0.05 Degree celsius	Standard Deviation 0.431
Placebo	Change From Baseline in Body Temperature	Week 40; n= 62, 66	-0.03 Degree celsius	Standard Deviation 0.53
Placebo	Change From Baseline in Body Temperature	Week 44; n= 61, 65	-0.03 Degree celsius	Standard Deviation 0.55
Placebo	Change From Baseline in Body Temperature	Week 48; n= 61, 64	-0.04 Degree celsius	Standard Deviation 0.452
Placebo	Change From Baseline in Body Temperature	Week 52; n= 60, 65	-0.04 Degree celsius	Standard Deviation 0.423
Placebo	Change From Baseline in Body Temperature	Week 56; n= 61, 63	-0.08 Degree celsius	Standard Deviation 0.53
Placebo	Change From Baseline in Body Temperature	Week 60; n= 61, 64	0.03 Degree celsius	Standard Deviation 0.467
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 60; n= 61, 64	-0.02 Degree celsius	Standard Deviation 0.479
Mepolizumab 300mg	Change From Baseline in Body Temperature	Absolute Baseline; n= 68, 68	36.51 Degree celsius	Standard Deviation 0.462
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 32; n= 62, 67	-0.07 Degree celsius	Standard Deviation 0.355
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 4; n= 68, 68	-0.04 Degree celsius	Standard Deviation 0.411
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 48; n= 61, 64	-0.09 Degree celsius	Standard Deviation 0.414
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 8; n= 67,68	-0.02 Degree celsius	Standard Deviation 0.425
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 36; n= 62, 67	0.03 Degree celsius	Standard Deviation 0.468
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 12; n= 66, 68	-0.03 Degree celsius	Standard Deviation 0.447
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 56; n= 61, 63	-0.00 Degree celsius	Standard Deviation 0.402
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 16; n= 64, 68	-0.03 Degree celsius	Standard Deviation 0.432
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 40; n= 62, 66	-0.13 Degree celsius	Standard Deviation 0.406
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 20; n= 63, 68	-0.13 Degree celsius	Standard Deviation 0.376
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 52; n= 60, 65	-0.12 Degree celsius	Standard Deviation 0.541
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 24; n= 62, 67	-0.06 Degree celsius	Standard Deviation 0.389
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 44; n= 61, 65	-0.08 Degree celsius	Standard Deviation 0.396
Mepolizumab 300mg	Change From Baseline in Body Temperature	Week 28; n= 63, 67	-0.14 Degree celsius	Standard Deviation 0.411

Secondary

Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels

Blood samples were collected to evaluate change from Baseline in calcium, chloride, cholesterol, glucose, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, phosphorus, potassium, sodium, urea nitrogen and very low density lipoprotein (VLDL) cholesterol values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured. NA indicates that data were not available.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 16; n= 1, 1	-0.400 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 16; n= 65, 68	0.000 millimoles per liter (mmol/L)	Standard Deviation 0.1091
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 20; n= 63, 68	0.002 millimoles per liter (mmol/L)	Standard Deviation 0.0882
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 24; n= 63, 66	0.001 millimoles per liter (mmol/L)	Standard Deviation 0.0901
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 28; n= 61, 66	0.001 millimoles per liter (mmol/L)	Standard Deviation 0.0962
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 32; n= 61, 67	-0.000 millimoles per liter (mmol/L)	Standard Deviation 0.0911
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 36; n= 60, 67	-0.006 millimoles per liter (mmol/L)	Standard Deviation 0.0931
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 40; n= 61, 66	0.014 millimoles per liter (mmol/L)	Standard Deviation 0.1126
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 44; n= 61, 66	0.016 millimoles per liter (mmol/L)	Standard Deviation 0.1144
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 48; n= 61, 64	-0.007 millimoles per liter (mmol/L)	Standard Deviation 0.1007
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 52; n= 60, 65	-0.008 millimoles per liter (mmol/L)	Standard Deviation 0.1001
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 56; n= 61, 63	-0.008 millimoles per liter (mmol/L)	Standard Deviation 0.0931
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 60; n= 60, 65	-0.025 millimoles per liter (mmol/L)	Standard Deviation 0.0946
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Chloride; Baseline; n= 68, 68	103.4 millimoles per liter (mmol/L)	Standard Deviation 2.05
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 4; n= 68, 68	0.6 millimoles per liter (mmol/L)	Standard Deviation 1.97
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 8; n= 67, 66	0.9 millimoles per liter (mmol/L)	Standard Deviation 2.05
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 12; n= 65, 68	0.7 millimoles per liter (mmol/L)	Standard Deviation 2.32
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 16; n= 65, 68	0.5 millimoles per liter (mmol/L)	Standard Deviation 2.08
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 20; n= 63, 68	0.3 millimoles per liter (mmol/L)	Standard Deviation 2.38
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 24; n= 63, 66	0.6 millimoles per liter (mmol/L)	Standard Deviation 2.51
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 28; n= 62, 66	0.7 millimoles per liter (mmol/L)	Standard Deviation 2.17
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 32; n= 61, 67	0.4 millimoles per liter (mmol/L)	Standard Deviation 2.24
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 36; n= 60, 67	0.8 millimoles per liter (mmol/L)	Standard Deviation 2.53
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 40; n= 61, 66	0.9 millimoles per liter (mmol/L)	Standard Deviation 2.22
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 44; n= 61, 66	0.5 millimoles per liter (mmol/L)	Standard Deviation 2.13
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 48; n= 61, 64	0.5 millimoles per liter (mmol/L)	Standard Deviation 2.38
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 52; n= 60, 65	0.3 millimoles per liter (mmol/L)	Standard Deviation 2.26
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 56; n= 61, 63	0.7 millimoles per liter (mmol/L)	Standard Deviation 2.27
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 60; n= 60, 65	0.4 millimoles per liter (mmol/L)	Standard Deviation 2.01
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Cholesterol; Baseline; n= 68, 68	5.771 millimoles per liter (mmol/L)	Standard Deviation 1.2033
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 8; n= 2, 0	-0.250 millimoles per liter (mmol/L)	Standard Deviation 0.1414
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 12; n= 1, 0	0.050 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Calcium; Baseline; n= 68, 68	2.365 millimoles per liter (mmol/L)	Standard Deviation 0.0864
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 20; n= 1, 1	0.050 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 52; n= 60, 65	-0.006 millimoles per liter (mmol/L)	Standard Deviation 0.9364
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 56; n= 1, 0	-0.220 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Glucose; Baseline; n= 68, 68	5.76 millimoles per liter (mmol/L)	Standard Deviation 2
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 4; n= 68, 68	0.27 millimoles per liter (mmol/L)	Standard Deviation 1.619
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 8; n= 67, 66	0.09 millimoles per liter (mmol/L)	Standard Deviation 1.695
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 12; n= 65, 68	0.27 millimoles per liter (mmol/L)	Standard Deviation 1.961
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 16; n= 65, 68	0.03 millimoles per liter (mmol/L)	Standard Deviation 1.454
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 20; n= 63, 68	0.25 millimoles per liter (mmol/L)	Standard Deviation 1.644
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 24; n= 63, 66	0.02 millimoles per liter (mmol/L)	Standard Deviation 1.588
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 28; n= 62, 66	0.14 millimoles per liter (mmol/L)	Standard Deviation 1.613
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 32; n= 61, 67	-0.03 millimoles per liter (mmol/L)	Standard Deviation 1.808
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 36; n= 60, 67	0.11 millimoles per liter (mmol/L)	Standard Deviation 1.525
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 40; n= 61, 66	0.34 millimoles per liter (mmol/L)	Standard Deviation 1.831
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 44; n= 61, 66	0.21 millimoles per liter (mmol/L)	Standard Deviation 1.766
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 48; n= 61, 64	0.32 millimoles per liter (mmol/L)	Standard Deviation 2.065
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 52; n= 60, 65	-0.17 millimoles per liter (mmol/L)	Standard Deviation 1.65
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 56; n= 61, 63	0.01 millimoles per liter (mmol/L)	Standard Deviation 1.718
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 60; n= 60, 65	0.20 millimoles per liter (mmol/L)	Standard Deviation 1.664
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute HDL cholesterol; Baseline; n= 68, 68	1.837 millimoles per liter (mmol/L)	Standard Deviation 0.454
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 8; n= 2, 0	-0.075 millimoles per liter (mmol/L)	Standard Deviation 0.0354
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 12; n= 1, 0	-0.100 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 16; n= 1, 1	0.400 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 20; n= 1, 1	0.000 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 52; n= 60, 65	-0.045 millimoles per liter (mmol/L)	Standard Deviation 0.2832
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 56; n= 1, 0	-0.060 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute LDL cholesterol; Baseline; n= 67, 68	3.261 millimoles per liter (mmol/L)	Standard Deviation 1.0808
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 8; n= 1, 0	-0.350 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 12; n= 1, 0	0.190 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 16; n= 1, 1	-0.730 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 20; n= 1, 1	-0.150 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 52; n= 58, 64	0.016 millimoles per liter (mmol/L)	Standard Deviation 0.7717
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 56; n= 1, 0	0.100 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Phosphate; Baseline; n= 68, 68	1.068 millimoles per liter (mmol/L)	Standard Deviation 0.1797
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 4; n= 68, 68	-0.027 millimoles per liter (mmol/L)	Standard Deviation 0.2183
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 8; n= 67, 66	-0.004 millimoles per liter (mmol/L)	Standard Deviation 0.1577
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 12; n= 65, 68	0.003 millimoles per liter (mmol/L)	Standard Deviation 0.1821
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 16; n= 65, 68	0.016 millimoles per liter (mmol/L)	Standard Deviation 0.1819
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 20; n= 63, 68	-0.001 millimoles per liter (mmol/L)	Standard Deviation 0.1611
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 24; n= 63, 66	-0.042 millimoles per liter (mmol/L)	Standard Deviation 0.1565
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 28; n= 62, 66	-0.025 millimoles per liter (mmol/L)	Standard Deviation 0.1819
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 32; n= 61, 67	-0.018 millimoles per liter (mmol/L)	Standard Deviation 0.1975
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 36; n= 60, 67	-0.038 millimoles per liter (mmol/L)	Standard Deviation 0.2159
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 40; n= 61, 66	-0.029 millimoles per liter (mmol/L)	Standard Deviation 0.1822
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 44; n= 61, 66	-0.018 millimoles per liter (mmol/L)	Standard Deviation 0.2104
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 48; n= 61, 64	-0.053 millimoles per liter (mmol/L)	Standard Deviation 0.1931
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 52; n= 60, 65	0.005 millimoles per liter (mmol/L)	Standard Deviation 0.1939
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 56; n= 61, 63	0.019 millimoles per liter (mmol/L)	Standard Deviation 0.2962
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 60; n= 60, 65	-0.035 millimoles per liter (mmol/L)	Standard Deviation 0.2125
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Potassium; Baseline; n= 68, 68	4.11 millimoles per liter (mmol/L)	Standard Deviation 0.348
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 4; n= 68, 68	0.05 millimoles per liter (mmol/L)	Standard Deviation 0.378
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 8; n= 67, 66	0.01 millimoles per liter (mmol/L)	Standard Deviation 0.309
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 12; n= 65, 68	-0.04 millimoles per liter (mmol/L)	Standard Deviation 0.318
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 16; n= 65, 68	0.06 millimoles per liter (mmol/L)	Standard Deviation 0.34
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 20; n= 63, 68	0.08 millimoles per liter (mmol/L)	Standard Deviation 0.382
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 24; n= 63, 66	-0.02 millimoles per liter (mmol/L)	Standard Deviation 0.298
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 28; n= 61, 66	0.07 millimoles per liter (mmol/L)	Standard Deviation 0.338
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 32; n= 61, 67	0.04 millimoles per liter (mmol/L)	Standard Deviation 0.34
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 36; n= 60, 67	0.02 millimoles per liter (mmol/L)	Standard Deviation 0.291
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 40; n= 61, 66	0.08 millimoles per liter (mmol/L)	Standard Deviation 0.419
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 44; n= 61, 66	0.08 millimoles per liter (mmol/L)	Standard Deviation 0.383
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 48; n= 61, 64	0.09 millimoles per liter (mmol/L)	Standard Deviation 0.367
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 52; n= 60, 65	0.05 millimoles per liter (mmol/L)	Standard Deviation 0.344
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 56; n= 61, 63	0.08 millimoles per liter (mmol/L)	Standard Deviation 0.379
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 60; n= 60, 65	0.00 millimoles per liter (mmol/L)	Standard Deviation 0.358
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Sodium; Baseline; n= 68, 68	139.8 millimoles per liter (mmol/L)	Standard Deviation 2.03
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 4; n= 68, 68	0.2 millimoles per liter (mmol/L)	Standard Deviation 1.86
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 8; n= 67, 66	0.4 millimoles per liter (mmol/L)	Standard Deviation 2.06
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 12; n= 65, 68	0.1 millimoles per liter (mmol/L)	Standard Deviation 1.99
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 16; n= 65, 68	0.0 millimoles per liter (mmol/L)	Standard Deviation 1.46
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 20; n= 63, 68	0.0 millimoles per liter (mmol/L)	Standard Deviation 1.88
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 24; n= 63, 66	0.2 millimoles per liter (mmol/L)	Standard Deviation 1.94
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 28; n= 62, 66	0.5 millimoles per liter (mmol/L)	Standard Deviation 1.71
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 32; n= 61, 67	0.3 millimoles per liter (mmol/L)	Standard Deviation 1.92
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 36; n= 60, 67	0.4 millimoles per liter (mmol/L)	Standard Deviation 2.1
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 40; n= 61, 66	0.2 millimoles per liter (mmol/L)	Standard Deviation 2.42
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 44; n= 61, 66	0.1 millimoles per liter (mmol/L)	Standard Deviation 1.77
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 48; n= 61, 64	0.1 millimoles per liter (mmol/L)	Standard Deviation 2.03
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 52; n= 60, 65	0.4 millimoles per liter (mmol/L)	Standard Deviation 1.79
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 56; n= 61, 63	0.4 millimoles per liter (mmol/L)	Standard Deviation 2.15
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 60; n= 60, 65	-0.1 millimoles per liter (mmol/L)	Standard Deviation 2.04
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Urea; Baseline; n= 68, 68	5.94 millimoles per liter (mmol/L)	Standard Deviation 1.451
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 4; n= 68, 68	-0.08 millimoles per liter (mmol/L)	Standard Deviation 1.412
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 8; n= 67, 66	-0.23 millimoles per liter (mmol/L)	Standard Deviation 1.564
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 12; n= 65, 68	-0.15 millimoles per liter (mmol/L)	Standard Deviation 1.414
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 16; n= 65, 68	-0.07 millimoles per liter (mmol/L)	Standard Deviation 1.569
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 20; n= 63, 68	-0.21 millimoles per liter (mmol/L)	Standard Deviation 1.465
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 24; n= 63, 66	-0.28 millimoles per liter (mmol/L)	Standard Deviation 1.513
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 28; n= 62, 66	-0.21 millimoles per liter (mmol/L)	Standard Deviation 1.525
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 32; n= 61, 67	-0.11 millimoles per liter (mmol/L)	Standard Deviation 1.32
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 36; n= 60, 67	-0.27 millimoles per liter (mmol/L)	Standard Deviation 1.407
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 40; n= 61, 66	-0.44 millimoles per liter (mmol/L)	Standard Deviation 1.377
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 44; n= 61, 66	-0.32 millimoles per liter (mmol/L)	Standard Deviation 1.731
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 48; n= 61, 64	-0.36 millimoles per liter (mmol/L)	Standard Deviation 1.422
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 52; n= 60, 65	-0.19 millimoles per liter (mmol/L)	Standard Deviation 1.737
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 56; n= 61, 63	-0.11 millimoles per liter (mmol/L)	Standard Deviation 1.495
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 60; n= 60, 65	-0.09 millimoles per liter (mmol/L)	Standard Deviation 1.546
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute VLDL cholesterol; Baseline; n= 67, 68	0.680 millimoles per liter (mmol/L)	Standard Deviation 0.2846
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 8; n= 1, 0	0.100 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 12; n= 1, 0	-0.040 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 16; n= 1, 1	-0.070 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 20; n= 1, 1	0.200 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 52; n= 58, 64	-0.019 millimoles per liter (mmol/L)	Standard Deviation 0.3229
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 56; n= 1, 0	-0.260 millimoles per liter (mmol/L)	—
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 4; n= 68, 68	-0.011 millimoles per liter (mmol/L)	Standard Deviation 0.0836
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 8; n= 67, 66	-0.013 millimoles per liter (mmol/L)	Standard Deviation 0.0877
Placebo	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 12; n= 65, 68	-0.013 millimoles per liter (mmol/L)	Standard Deviation 0.0844
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Calcium; Baseline; n= 68, 68	2.382 millimoles per liter (mmol/L)	Standard Deviation 0.1189
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 12; n= 65, 68	-0.1 millimoles per liter (mmol/L)	Standard Deviation 2.28
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 4; n= 68, 68	-0.012 millimoles per liter (mmol/L)	Standard Deviation 0.12
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 4; n= 68, 68	0.014 millimoles per liter (mmol/L)	Standard Deviation 0.1833
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 8; n= 67, 66	-0.010 millimoles per liter (mmol/L)	Standard Deviation 0.1003
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 52; n= 60, 65	-0.18 millimoles per liter (mmol/L)	Standard Deviation 1.128
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 12; n= 65, 68	-0.026 millimoles per liter (mmol/L)	Standard Deviation 0.0889
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 8; n= 67, 66	0.024 millimoles per liter (mmol/L)	Standard Deviation 0.2239
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 16; n= 65, 68	-0.029 millimoles per liter (mmol/L)	Standard Deviation 0.1018
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 16; n= 65, 68	-0.1 millimoles per liter (mmol/L)	Standard Deviation 1.91
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 20; n= 63, 68	-0.016 millimoles per liter (mmol/L)	Standard Deviation 0.1032
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 12; n= 65, 68	0.019 millimoles per liter (mmol/L)	Standard Deviation 0.2181
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 24; n= 63, 66	-0.013 millimoles per liter (mmol/L)	Standard Deviation 0.1111
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 20; n= 63, 68	-0.23 millimoles per liter (mmol/L)	Standard Deviation 1.286
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 28; n= 61, 66	-0.001 millimoles per liter (mmol/L)	Standard Deviation 0.1039
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 16; n= 65, 68	0.016 millimoles per liter (mmol/L)	Standard Deviation 0.2205
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 32; n= 61, 67	-0.006 millimoles per liter (mmol/L)	Standard Deviation 0.0977
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 20; n= 63, 68	0.1 millimoles per liter (mmol/L)	Standard Deviation 2.09
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 36; n= 60, 67	-0.006 millimoles per liter (mmol/L)	Standard Deviation 0.1133
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 20; n= 63, 68	0.019 millimoles per liter (mmol/L)	Standard Deviation 0.2087
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 40; n= 61, 66	0.005 millimoles per liter (mmol/L)	Standard Deviation 0.1115
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 36; n= 0, 1	-0.230 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 44; n= 61, 66	-0.020 millimoles per liter (mmol/L)	Standard Deviation 0.1115
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 24; n= 63, 66	0.007 millimoles per liter (mmol/L)	Standard Deviation 0.2142
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 48; n= 61, 64	-0.018 millimoles per liter (mmol/L)	Standard Deviation 0.1002
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 24; n= 63, 66	0.0 millimoles per liter (mmol/L)	Standard Deviation 1.95
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 52; n= 60, 65	-0.027 millimoles per liter (mmol/L)	Standard Deviation 0.111
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 28; n= 62, 66	0.003 millimoles per liter (mmol/L)	Standard Deviation 0.2539
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 56; n= 61, 63	-0.015 millimoles per liter (mmol/L)	Standard Deviation 0.0994
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 24; n= 63, 66	-0.12 millimoles per liter (mmol/L)	Standard Deviation 1.172
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Calcium; Week 60; n= 60, 65	-0.019 millimoles per liter (mmol/L)	Standard Deviation 0.1058
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 32; n= 61, 67	0.040 millimoles per liter (mmol/L)	Standard Deviation 0.2172
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Chloride; Baseline; n= 68, 68	104.0 millimoles per liter (mmol/L)	Standard Deviation 2.21
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 28; n= 62, 66	0.0 millimoles per liter (mmol/L)	Standard Deviation 2.23
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 4; n= 68, 68	0.2 millimoles per liter (mmol/L)	Standard Deviation 2
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 36; n= 60, 67	0.023 millimoles per liter (mmol/L)	Standard Deviation 0.226
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 8; n= 67, 66	0.5 millimoles per liter (mmol/L)	Standard Deviation 2.06
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 56; n= 61, 63	-0.13 millimoles per liter (mmol/L)	Standard Deviation 1.539
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 12; n= 65, 68	0.7 millimoles per liter (mmol/L)	Standard Deviation 2.2
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 40; n= 61, 66	0.026 millimoles per liter (mmol/L)	Standard Deviation 0.2213
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 16; n= 65, 68	0.8 millimoles per liter (mmol/L)	Standard Deviation 1.95
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 32; n= 61, 67	0.1 millimoles per liter (mmol/L)	Standard Deviation 2.13
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 20; n= 63, 68	0.7 millimoles per liter (mmol/L)	Standard Deviation 2.04
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 44; n= 61, 66	0.041 millimoles per liter (mmol/L)	Standard Deviation 0.224
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 24; n= 63, 66	0.8 millimoles per liter (mmol/L)	Standard Deviation 2.2
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 28; n= 62, 66	-0.22 millimoles per liter (mmol/L)	Standard Deviation 1.35
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 28; n= 62, 66	0.8 millimoles per liter (mmol/L)	Standard Deviation 2.59
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 48; n= 61, 64	-0.020 millimoles per liter (mmol/L)	Standard Deviation 0.2443
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 32; n= 61, 67	0.5 millimoles per liter (mmol/L)	Standard Deviation 2.32
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 36; n= 60, 67	0.0 millimoles per liter (mmol/L)	Standard Deviation 1.95
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 36; n= 60, 67	0.6 millimoles per liter (mmol/L)	Standard Deviation 2.08
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 52; n= 60, 65	0.053 millimoles per liter (mmol/L)	Standard Deviation 0.2988
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 40; n= 61, 66	0.7 millimoles per liter (mmol/L)	Standard Deviation 2.13
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 16; n= 1, 1	0.640 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 44; n= 61, 66	0.6 millimoles per liter (mmol/L)	Standard Deviation 2.55
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 56; n= 61, 63	0.043 millimoles per liter (mmol/L)	Standard Deviation 0.3066
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 48; n= 61, 64	0.5 millimoles per liter (mmol/L)	Standard Deviation 2.34
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 40; n= 61, 66	0.0 millimoles per liter (mmol/L)	Standard Deviation 2.18
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 52; n= 60, 65	0.4 millimoles per liter (mmol/L)	Standard Deviation 2.24
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Phosphate; Week 60; n= 60, 65	-0.007 millimoles per liter (mmol/L)	Standard Deviation 0.2322
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 56; n= 61, 63	0.2 millimoles per liter (mmol/L)	Standard Deviation 2.06
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 32; n= 61, 67	-0.23 millimoles per liter (mmol/L)	Standard Deviation 1.359
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Chloride; Week 60; n= 60, 65	0.4 millimoles per liter (mmol/L)	Standard Deviation 2.2
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Potassium; Baseline; n= 68, 68	4.10 millimoles per liter (mmol/L)	Standard Deviation 0.359
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Cholesterol; Baseline; n= 68, 68	5.788 millimoles per liter (mmol/L)	Standard Deviation 1.2386
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 44; n= 61, 66	-0.2 millimoles per liter (mmol/L)	Standard Deviation 2.02
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 4; n= 68, 68	-0.02 millimoles per liter (mmol/L)	Standard Deviation 0.345
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 60; n= 60, 65	-0.10 millimoles per liter (mmol/L)	Standard Deviation 1.17
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 16; n= 1, 1	-0.300 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 8; n= 67, 66	0.02 millimoles per liter (mmol/L)	Standard Deviation 0.323
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 20; n= 1, 1	-0.300 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 24; n= 0, 1	-0.560 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 36; n= 0, 1	0.420 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 48; n= 61, 64	-0.4 millimoles per liter (mmol/L)	Standard Deviation 1.97
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Cholesterol; Week 52; n= 60, 65	-0.384 millimoles per liter (mmol/L)	Standard Deviation 0.8798
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 12; n= 65, 68	0.01 millimoles per liter (mmol/L)	Standard Deviation 0.296
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 36; n= 60, 67	-0.32 millimoles per liter (mmol/L)	Standard Deviation 1.391
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Glucose; Baseline; n= 68, 68	5.35 millimoles per liter (mmol/L)	Standard Deviation 1.195
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 16; n= 65, 68	0.05 millimoles per liter (mmol/L)	Standard Deviation 0.317
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 4; n= 68, 68	-0.01 millimoles per liter (mmol/L)	Standard Deviation 1.05
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 52; n= 60, 65	-0.2 millimoles per liter (mmol/L)	Standard Deviation 2.17
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 8; n= 67, 66	0.07 millimoles per liter (mmol/L)	Standard Deviation 0.986
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 20; n= 63, 68	0.01 millimoles per liter (mmol/L)	Standard Deviation 0.372
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 12; n= 65, 68	0.26 millimoles per liter (mmol/L)	Standard Deviation 1.079
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 52; n= 58, 64	-0.051 millimoles per liter (mmol/L)	Standard Deviation 0.1927
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 16; n= 65, 68	0.04 millimoles per liter (mmol/L)	Standard Deviation 1.077
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 24; n= 63, 66	0.04 millimoles per liter (mmol/L)	Standard Deviation 0.35
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 20; n= 63, 68	-0.03 millimoles per liter (mmol/L)	Standard Deviation 1.351
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 56; n= 61, 63	-0.5 millimoles per liter (mmol/L)	Standard Deviation 2.08
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 24; n= 63, 66	0.16 millimoles per liter (mmol/L)	Standard Deviation 1.211
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 28; n= 61, 66	0.10 millimoles per liter (mmol/L)	Standard Deviation 0.382
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 28; n= 62, 66	0.21 millimoles per liter (mmol/L)	Standard Deviation 1.551
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 40; n= 61, 66	-0.23 millimoles per liter (mmol/L)	Standard Deviation 1.375
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 32; n= 61, 67	-0.14 millimoles per liter (mmol/L)	Standard Deviation 1.162
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 32; n= 61, 67	0.11 millimoles per liter (mmol/L)	Standard Deviation 0.305
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 36; n= 60, 67	0.03 millimoles per liter (mmol/L)	Standard Deviation 1.003
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 60; n= 60, 65	-0.3 millimoles per liter (mmol/L)	Standard Deviation 2.36
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 40; n= 61, 66	-0.03 millimoles per liter (mmol/L)	Standard Deviation 1.305
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 36; n= 60, 67	0.01 millimoles per liter (mmol/L)	Standard Deviation 0.351
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 44; n= 61, 66	-0.05 millimoles per liter (mmol/L)	Standard Deviation 0.891
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute VLDL cholesterol; Baseline; n= 67, 68	0.646 millimoles per liter (mmol/L)	Standard Deviation 0.2841
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 48; n= 61, 64	0.21 millimoles per liter (mmol/L)	Standard Deviation 1.74
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 40; n= 61, 66	0.14 millimoles per liter (mmol/L)	Standard Deviation 0.313
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 52; n= 60, 65	0.02 millimoles per liter (mmol/L)	Standard Deviation 1.258
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Urea; Baseline; n= 68, 68	5.79 millimoles per liter (mmol/L)	Standard Deviation 1.629
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 56; n= 61, 63	0.13 millimoles per liter (mmol/L)	Standard Deviation 1.852
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 44; n= 61, 66	0.09 millimoles per liter (mmol/L)	Standard Deviation 0.341
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Glucose; Week 60; n= 60, 65	0.11 millimoles per liter (mmol/L)	Standard Deviation 1.483
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 44; n= 61, 66	-0.19 millimoles per liter (mmol/L)	Standard Deviation 1.698
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute HDL cholesterol; Baseline; n= 68, 68	1.937 millimoles per liter (mmol/L)	Standard Deviation 0.5606
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 48; n= 61, 64	0.05 millimoles per liter (mmol/L)	Standard Deviation 0.349
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 4; n= 68, 68	0.09 millimoles per liter (mmol/L)	Standard Deviation 1.241
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 52; n= 60, 65	0.01 millimoles per liter (mmol/L)	Standard Deviation 0.329
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 16; n= 1, 1	-0.150 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 20; n= 1, 1	0.490 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 20; n= 1, 1	-0.250 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 24; n= 0, 1	-0.390 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 36; n= 0, 1	0.400 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 56; n= 61, 63	0.08 millimoles per liter (mmol/L)	Standard Deviation 0.378
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	HDL cholesterol; Week 52; n= 60, 65	-0.150 millimoles per liter (mmol/L)	Standard Deviation 0.3146
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 8; n= 67, 66	0.20 millimoles per liter (mmol/L)	Standard Deviation 1.206
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Potassium; Week 60; n= 60, 65	0.10 millimoles per liter (mmol/L)	Standard Deviation 0.39
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute LDL cholesterol; Baseline; n= 67, 68	3.205 millimoles per liter (mmol/L)	Standard Deviation 1.0992
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 48; n= 61, 64	-0.09 millimoles per liter (mmol/L)	Standard Deviation 1.429
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Sodium; Baseline; n= 68, 68	140.3 millimoles per liter (mmol/L)	Standard Deviation 1.83
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 12; n= 65, 68	-0.10 millimoles per liter (mmol/L)	Standard Deviation 1.217
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 16; n= 1, 1	-0.790 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 4; n= 68, 68	0.3 millimoles per liter (mmol/L)	Standard Deviation 2.03
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 20; n= 1, 1	-0.540 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 24; n= 0, 1	0.040 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 36; n= 0, 1	0.250 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	VLDL cholesterol; Week 24; n= 0, 1	-0.210 millimoles per liter (mmol/L)	—
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	LDL cholesterol; Week 52; n= 58, 64	-0.215 millimoles per liter (mmol/L)	Standard Deviation 0.8079
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Sodium; Week 8; n= 67, 66	0.2 millimoles per liter (mmol/L)	Standard Deviation 1.89
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Urea; Week 16; n= 65, 68	0.00 millimoles per liter (mmol/L)	Standard Deviation 1.317
Mepolizumab 300mg	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels	Absolute Phosphate; Baseline; n= 68, 68	1.066 millimoles per liter (mmol/L)	Standard Deviation 0.1939

Secondary

Change From Baseline in Clinical Chemistry Parameter of Troponin Levels

Blood samples were collected to evaluate change from Baseline in troponin values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Absolute Troponin; Baseline; n= 68, 68	0.013 µg/L	Standard Deviation 0.011
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 4; n= 68, 66	-0.001 µg/L	Standard Deviation 0.0106
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 8; n= 67, 67	-0.002 µg/L	Standard Deviation 0.0111
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 12; n= 64, 67	-0.002 µg/L	Standard Deviation 0.0108
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 16; n= 65, 68	-0.002 µg/L	Standard Deviation 0.0104
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 20; n= 61, 68	-0.002 µg/L	Standard Deviation 0.0105
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 24; n= 62, 67	-0.002 µg/L	Standard Deviation 0.0098
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 28; n= 63, 66	-0.003 µg/L	Standard Deviation 0.0102
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 32; n= 61, 67	-0.003 µg/L	Standard Deviation 0.01
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 36; n= 61, 67	-0.002 µg/L	Standard Deviation 0.0107
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 40; n= 61, 66	-0.001 µg/L	Standard Deviation 0.0117
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 44; n= 61, 65	-0.000 µg/L	Standard Deviation 0.0068
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 48; n= 60, 65	0.017 µg/L	Standard Deviation 0.1479
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 52; n= 60, 65	-0.002 µg/L	Standard Deviation 0.0114
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 56; n= 61, 63	-0.003 µg/L	Standard Deviation 0.0112
Placebo	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 60; n= 59, 65	-0.003 µg/L	Standard Deviation 0.0109
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 60; n= 59, 65	-0.001 µg/L	Standard Deviation 0.0093
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Absolute Troponin; Baseline; n= 68, 68	0.013 µg/L	Standard Deviation 0.0092
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 32; n= 61, 67	-0.002 µg/L	Standard Deviation 0.0092
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 4; n= 68, 66	0.008 µg/L	Standard Deviation 0.0717
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 48; n= 60, 65	-0.001 µg/L	Standard Deviation 0.0101
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 8; n= 67, 67	0.001 µg/L	Standard Deviation 0.0089
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 36; n= 61, 67	0.000 µg/L	Standard Deviation 0.0185
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 12; n= 64, 67	-0.001 µg/L	Standard Deviation 0.0053
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 56; n= 61, 63	-0.002 µg/L	Standard Deviation 0.0086
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 16; n= 65, 68	0.002 µg/L	Standard Deviation 0.0272
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 40; n= 61, 66	-0.002 µg/L	Standard Deviation 0.009
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 20; n= 61, 68	-0.001 µg/L	Standard Deviation 0.0089
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 52; n= 60, 65	-0.001 µg/L	Standard Deviation 0.0111
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 24; n= 62, 67	0.004 µg/L	Standard Deviation 0.0535
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 44; n= 61, 65	-0.001 µg/L	Standard Deviation 0.0095
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameter of Troponin Levels	Troponin; Week 28; n= 63, 66	-0.002 µg/L	Standard Deviation 0.009

Secondary

Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels

Blood samples were collected to evaluate change from Baseline in ALT, Alk.phosph., AST, creatinine kinase, GGT and lactate dehydro values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 4; n= 68, 68	0.0 International Unit per Liter (IU/L)	Standard Deviation 4.41
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 28; n= 61, 66	-0.9 International Unit per Liter (IU/L)	Standard Deviation 5.34
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 12; n= 65, 68	-0.9 International Unit per Liter (IU/L)	Standard Deviation 4.53
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 32; n= 61, 67	-0.2 International Unit per Liter (IU/L)	Standard Deviation 4.91
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 60; n= 60, 65	-0.3 International Unit per Liter (IU/L)	Standard Deviation 7.33
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 40; n= 61, 66	0.5 International Unit per Liter (IU/L)	Standard Deviation 5.51
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 16; n= 65, 68	-0.4 International Unit per Liter (IU/L)	Standard Deviation 6.56
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 36; n= 60, 67	0.2 International Unit per Liter (IU/L)	Standard Deviation 4.68
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 48; n= 61, 64	1.1 International Unit per Liter (IU/L)	Standard Deviation 6.86
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 20; n= 63, 68	-0.3 International Unit per Liter (IU/L)	Standard Deviation 6.25
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 52; n= 60, 65	0.9 International Unit per Liter (IU/L)	Standard Deviation 6.84
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 44; n= 61, 66	0.4 International Unit per Liter (IU/L)	Standard Deviation 5.77
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 24; n= 63, 66	-1.3 International Unit per Liter (IU/L)	Standard Deviation 5.38
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 60; n= 60, 65	-0.4 International Unit per Liter (IU/L)	Standard Deviation 5.24
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 56; n= 61, 63	-0.2 International Unit per Liter (IU/L)	Standard Deviation 4.92
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute Creatinine kinase; Baseline; n= 68, 68	99.0 International Unit per Liter (IU/L)	Standard Deviation 75.99
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 28; n= 62, 66	-0.9 International Unit per Liter (IU/L)	Standard Deviation 6.73
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 4; n= 68, 68	-2.4 International Unit per Liter (IU/L)	Standard Deviation 83.23
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 44; n= 61, 66	0.9 International Unit per Liter (IU/L)	Standard Deviation 9.68
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 12; n= 65, 68	5.4 International Unit per Liter (IU/L)	Standard Deviation 93.24
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 32; n= 61, 67	-0.7 International Unit per Liter (IU/L)	Standard Deviation 6.79
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 16; n= 65, 68	15.8 International Unit per Liter (IU/L)	Standard Deviation 125.84
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 8; n= 67, 66	-5.0 International Unit per Liter (IU/L)	Standard Deviation 62.41
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 20; n= 63, 68	1.3 International Unit per Liter (IU/L)	Standard Deviation 78.35
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 36; n= 60, 67	-0.1 International Unit per Liter (IU/L)	Standard Deviation 6.21
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 24; n= 63, 66	-0.6 International Unit per Liter (IU/L)	Standard Deviation 56.55
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 12; n= 65, 68	-1.9 International Unit per Liter (IU/L)	Standard Deviation 8.36
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 28; n= 62, 66	-15.9 International Unit per Liter (IU/L)	Standard Deviation 59.38
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 32; n= 61, 67	-13.1 International Unit per Liter (IU/L)	Standard Deviation 59.29
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 16; n= 65, 68	-1.3 International Unit per Liter (IU/L)	Standard Deviation 9.35
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 36; n= 60, 67	-12.0 International Unit per Liter (IU/L)	Standard Deviation 65.11
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute Alk.phosph.; Baseline; n= 68, 68	61.2 International Unit per Liter (IU/L)	Standard Deviation 17.83
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 40; n= 61, 66	2.6 International Unit per Liter (IU/L)	Standard Deviation 91.89
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 44; n= 61, 66	5.8 International Unit per Liter (IU/L)	Standard Deviation 86.76
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 20; n= 63, 68	0.0 International Unit per Liter (IU/L)	Standard Deviation 11.24
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 48; n= 61, 64	-8.1 International Unit per Liter (IU/L)	Standard Deviation 70.09
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 52; n= 60, 65	0.9 International Unit per Liter (IU/L)	Standard Deviation 67.51
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 52; n= 60, 65	1.5 International Unit per Liter (IU/L)	Standard Deviation 10.42
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 60; n= 60, 65	-10.3 International Unit per Liter (IU/L)	Standard Deviation 65.83
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 28; n= 62, 66	0.2 International Unit per Liter (IU/L)	Standard Deviation 10.95
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute GGT; Baseline; n= 68, 68	30.8 International Unit per Liter (IU/L)	Standard Deviation 25.49
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 56; n= 61, 63	-8.7 International Unit per Liter (IU/L)	Standard Deviation 60.58
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 4; n= 68, 68	0.2 International Unit per Liter (IU/L)	Standard Deviation 11.7
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 32; n= 61, 67	0.2 International Unit per Liter (IU/L)	Standard Deviation 11.14
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 8; n= 67, 66	-1.0 International Unit per Liter (IU/L)	Standard Deviation 8.59
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk.phosph.; Week 4; n= 68, 68	-0.9 International Unit per Liter (IU/L)	Standard Deviation 6.65
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 12; n= 65, 68	-2.9 International Unit per Liter (IU/L)	Standard Deviation 6.68
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 36; n= 60, 67	0.2 International Unit per Liter (IU/L)	Standard Deviation 10.42
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 16; n= 65, 68	-2.1 International Unit per Liter (IU/L)	Standard Deviation 10.18
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 40; n= 61, 66	1.0 International Unit per Liter (IU/L)	Standard Deviation 10.08
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 20; n= 63, 68	1.7 International Unit per Liter (IU/L)	Standard Deviation 19.02
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 36; n= 60, 67	-2.1 International Unit per Liter (IU/L)	Standard Deviation 10.64
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 24; n= 63, 66	-1.7 International Unit per Liter (IU/L)	Standard Deviation 11.83
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 44; n= 61, 66	1.1 International Unit per Liter (IU/L)	Standard Deviation 12.55
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 28; n= 62, 66	-1.9 International Unit per Liter (IU/L)	Standard Deviation 11.71
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 40; n= 61, 66	0.3 International Unit per Liter (IU/L)	Standard Deviation 9.01
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 32; n= 61, 67	-1.5 International Unit per Liter (IU/L)	Standard Deviation 15.77
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 40; n= 61, 66	-0.2 International Unit per Liter (IU/L)	Standard Deviation 16.05
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 48; n= 61, 64	1.2 International Unit per Liter (IU/L)	Standard Deviation 11.66
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 44; n= 61, 66	-2.9 International Unit per Liter (IU/L)	Standard Deviation 8.26
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 48; n= 61, 64	0.9 International Unit per Liter (IU/L)	Standard Deviation 18.91
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 52; n= 60, 65	0.3 International Unit per Liter (IU/L)	Standard Deviation 12.3
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 52; n= 60, 65	-1.6 International Unit per Liter (IU/L)	Standard Deviation 16.44
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 60; n= 60, 65	-4.8 International Unit per Liter (IU/L)	Standard Deviation 16.45
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk.phosph.; Week 8; n= 67, 66	-1.7 International Unit per Liter (IU/L)	Standard Deviation 9.95
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 56; n= 61, 63	-0.9 International Unit per Liter (IU/L)	Standard Deviation 12.04
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 4; n= 68, 68	-3.6 International Unit per Liter (IU/L)	Standard Deviation 19.73
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 56; n= 61, 63	-5.0 International Unit per Liter (IU/L)	Standard Deviation 16.77
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 8; n= 67, 66	-8.2 International Unit per Liter (IU/L)	Standard Deviation 29.91
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 60; n= 60, 65	-1.5 International Unit per Liter (IU/L)	Standard Deviation 13.16
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 12; n= 65, 68	-2.2 International Unit per Liter (IU/L)	Standard Deviation 27.17
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 56; n= 61, 63	-0.1 International Unit per Liter (IU/L)	Standard Deviation 7.35
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 16; n= 65, 68	-2.6 International Unit per Liter (IU/L)	Standard Deviation 32.13
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute AST; Baseline; n= 68, 68	19.3 International Unit per Liter (IU/L)	Standard Deviation 6.11
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 20; n= 63, 68	2.2 International Unit per Liter (IU/L)	Standard Deviation 26.8
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute Lactate dehydro; Baseline; n= 68, 68	186.5 International Unit per Liter (IU/L)	Standard Deviation 47.82
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 24; n= 63, 66	-4.3 International Unit per Liter (IU/L)	Standard Deviation 26.22
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute ALT; Baseline; n= 68, 68	19.9 International Unit per Liter (IU/L)	Standard Deviation 8.91
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 28; n= 61, 66	-8.5 International Unit per Liter (IU/L)	Standard Deviation 27.77
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 8; n= 67, 66	-0.4 International Unit per Liter (IU/L)	Standard Deviation 4.77
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 32; n= 61, 67	-8.3 International Unit per Liter (IU/L)	Standard Deviation 25.49
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 24; n= 63, 66	-1.1 International Unit per Liter (IU/L)	Standard Deviation 10.65
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 36; n= 60, 67	-3.6 International Unit per Liter (IU/L)	Standard Deviation 36.45
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 12; n= 65, 68	0.5 International Unit per Liter (IU/L)	Standard Deviation 4.41
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 40; n= 61, 66	-4.5 International Unit per Liter (IU/L)	Standard Deviation 35.81
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 4; n= 68, 68	0.2 International Unit per Liter (IU/L)	Standard Deviation 6.17
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 44; n= 61, 66	-2.7 International Unit per Liter (IU/L)	Standard Deviation 33.4
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 16; n= 65, 68	0.4 International Unit per Liter (IU/L)	Standard Deviation 5.48
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 48; n= 61, 64	0.8 International Unit per Liter (IU/L)	Standard Deviation 43.82
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 48; n= 61, 64	1.7 International Unit per Liter (IU/L)	Standard Deviation 9.04
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 52; n= 60, 65	-0.1 International Unit per Liter (IU/L)	Standard Deviation 34.99
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 20; n= 63, 68	0.8 International Unit per Liter (IU/L)	Standard Deviation 4.66
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 56; n= 61, 63	-5.2 International Unit per Liter (IU/L)	Standard Deviation 32.69
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 8; n= 67, 66	-0.9 International Unit per Liter (IU/L)	Standard Deviation 5.66
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 60; n= 60, 65	-3.5 International Unit per Liter (IU/L)	Standard Deviation 34.15
Placebo	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 24; n= 63, 66	0.0 International Unit per Liter (IU/L)	Standard Deviation 4.46
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 60; n= 60, 65	-12.4 International Unit per Liter (IU/L)	Standard Deviation 33.23
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 40; n= 61, 66	-2.3 International Unit per Liter (IU/L)	Standard Deviation 11.7
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 44; n= 61, 66	-2.7 International Unit per Liter (IU/L)	Standard Deviation 9.51
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 48; n= 61, 64	-1.6 International Unit per Liter (IU/L)	Standard Deviation 15.47
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 52; n= 60, 65	-2.8 International Unit per Liter (IU/L)	Standard Deviation 12.87
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 56; n= 61, 63	-3.6 International Unit per Liter (IU/L)	Standard Deviation 12.79
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 60; n= 60, 65	-4.7 International Unit per Liter (IU/L)	Standard Deviation 14.11
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute Alk.phosph.; Baseline; n= 68, 68	60.4 International Unit per Liter (IU/L)	Standard Deviation 20.9
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk.phosph.; Week 4; n= 68, 68	-3.2 International Unit per Liter (IU/L)	Standard Deviation 10.01
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk.phosph.; Week 8; n= 67, 66	-1.7 International Unit per Liter (IU/L)	Standard Deviation 11.56
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 36; n= 60, 67	4.8 International Unit per Liter (IU/L)	Standard Deviation 14.71
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 32; n= 61, 67	-1.3 International Unit per Liter (IU/L)	Standard Deviation 10.67
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 4; n= 68, 68	2.0 International Unit per Liter (IU/L)	Standard Deviation 60.92
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 40; n= 61, 66	2.8 International Unit per Liter (IU/L)	Standard Deviation 62.74
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 52; n= 60, 65	0.2 International Unit per Liter (IU/L)	Standard Deviation 53.45
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 32; n= 61, 67	-3.6 International Unit per Liter (IU/L)	Standard Deviation 17.87
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 36; n= 60, 67	-4.7 International Unit per Liter (IU/L)	Standard Deviation 14.96
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 52; n= 60, 65	-4.2 International Unit per Liter (IU/L)	Standard Deviation 13.53
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 56; n= 61, 63	-3.6 International Unit per Liter (IU/L)	Standard Deviation 17.02
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute ALT; Baseline; n= 68, 68	21.3 International Unit per Liter (IU/L)	Standard Deviation 14.22
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 4; n= 68, 68	-2.2 International Unit per Liter (IU/L)	Standard Deviation 8.59
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 8; n= 67, 66	-1.7 International Unit per Liter (IU/L)	Standard Deviation 10.14
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 12; n= 65, 68	-0.7 International Unit per Liter (IU/L)	Standard Deviation 12.65
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 16; n= 65, 68	-2.2 International Unit per Liter (IU/L)	Standard Deviation 9.73
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 20; n= 63, 68	-1.2 International Unit per Liter (IU/L)	Standard Deviation 12.3
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 24; n= 63, 66	-0.2 International Unit per Liter (IU/L)	Standard Deviation 15.77
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 28; n= 62, 66	-0.4 International Unit per Liter (IU/L)	Standard Deviation 13.62
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 32; n= 61, 67	-2.4 International Unit per Liter (IU/L)	Standard Deviation 11.3
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 12; n= 65, 68	-1.1 International Unit per Liter (IU/L)	Standard Deviation 12.99
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 16; n= 65, 68	-1.1 International Unit per Liter (IU/L)	Standard Deviation 14.61
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 20; n= 63, 68	4.4 International Unit per Liter (IU/L)	Standard Deviation 21.9
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 24; n= 63, 66	2.8 International Unit per Liter (IU/L)	Standard Deviation 17.64
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 28; n= 62, 66	4.9 International Unit per Liter (IU/L)	Standard Deviation 17.17
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 32; n= 61, 67	4.4 International Unit per Liter (IU/L)	Standard Deviation 15.83
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 40; n= 61, 66	6.2 International Unit per Liter (IU/L)	Standard Deviation 18.43
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 44; n= 61, 66	5.1 International Unit per Liter (IU/L)	Standard Deviation 16.53
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 48; n= 61, 64	5.1 International Unit per Liter (IU/L)	Standard Deviation 17.56
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 52; n= 60, 65	2.3 International Unit per Liter (IU/L)	Standard Deviation 14.47
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 56; n= 61, 63	1.7 International Unit per Liter (IU/L)	Standard Deviation 16.42
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Alk. phosph.; Week 60; n= 60, 65	1.0 International Unit per Liter (IU/L)	Standard Deviation 15.08
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute AST; Baseline; n= 68, 68	21.8 International Unit per Liter (IU/L)	Standard Deviation 10.73
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 4; n= 68, 68	-1.7 International Unit per Liter (IU/L)	Standard Deviation 8.61
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 8; n= 67, 66	-1.0 International Unit per Liter (IU/L)	Standard Deviation 8.21
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 12; n= 65, 68	-0.7 International Unit per Liter (IU/L)	Standard Deviation 9.62
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 16; n= 65, 68	-0.6 International Unit per Liter (IU/L)	Standard Deviation 7.9
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 20; n= 63, 68	-0.6 International Unit per Liter (IU/L)	Standard Deviation 8.49
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 24; n= 63, 66	-0.4 International Unit per Liter (IU/L)	Standard Deviation 10.44
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 28; n= 61, 66	-0.4 International Unit per Liter (IU/L)	Standard Deviation 10.59
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 36; n= 60, 67	-2.2 International Unit per Liter (IU/L)	Standard Deviation 9.61
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 40; n= 61, 66	-1.6 International Unit per Liter (IU/L)	Standard Deviation 8.97
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 44; n= 61, 66	-2.4 International Unit per Liter (IU/L)	Standard Deviation 9.02
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 48; n= 61, 64	-2.3 International Unit per Liter (IU/L)	Standard Deviation 10.14
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 52; n= 60, 65	-3.0 International Unit per Liter (IU/L)	Standard Deviation 10.49
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 56; n= 61, 63	-2.8 International Unit per Liter (IU/L)	Standard Deviation 10.64
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	AST; Week 60; n= 60, 65	-3.7 International Unit per Liter (IU/L)	Standard Deviation 10.92
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute Creatinine kinase; Baseline; n= 68, 68	88.8 International Unit per Liter (IU/L)	Standard Deviation 75.18
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 8; n= 67, 66	3.5 International Unit per Liter (IU/L)	Standard Deviation 50.48
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 12; n= 65, 68	6.1 International Unit per Liter (IU/L)	Standard Deviation 40.86
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 16; n= 65, 68	0.5 International Unit per Liter (IU/L)	Standard Deviation 49.65
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 20; n= 63, 68	6.5 International Unit per Liter (IU/L)	Standard Deviation 54.83
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 24; n= 63, 66	6.0 International Unit per Liter (IU/L)	Standard Deviation 66.69
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 28; n= 62, 66	6.3 International Unit per Liter (IU/L)	Standard Deviation 55.84
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 32; n= 61, 67	0.2 International Unit per Liter (IU/L)	Standard Deviation 49.68
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 36; n= 60, 67	4.9 International Unit per Liter (IU/L)	Standard Deviation 52.71
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 44; n= 61, 66	-2.4 International Unit per Liter (IU/L)	Standard Deviation 62.13
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 48; n= 61, 64	-2.6 International Unit per Liter (IU/L)	Standard Deviation 90.09
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 56; n= 61, 63	-0.2 International Unit per Liter (IU/L)	Standard Deviation 62.08
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Creatinine kinase; Week 60; n= 60, 65	0.4 International Unit per Liter (IU/L)	Standard Deviation 61.45
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute GGT; Baseline; n= 68, 68	30.1 International Unit per Liter (IU/L)	Standard Deviation 27.24
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 4; n= 68, 68	-2.0 International Unit per Liter (IU/L)	Standard Deviation 9.68
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 8; n= 67, 66	-0.6 International Unit per Liter (IU/L)	Standard Deviation 17.99
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 12; n= 65, 68	-1.9 International Unit per Liter (IU/L)	Standard Deviation 18.7
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 16; n= 65, 68	-1.5 International Unit per Liter (IU/L)	Standard Deviation 21.36
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 20; n= 63, 68	-1.1 International Unit per Liter (IU/L)	Standard Deviation 24.5
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 24; n= 63, 66	-3.3 International Unit per Liter (IU/L)	Standard Deviation 22.52
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 28; n= 62, 66	-3.1 International Unit per Liter (IU/L)	Standard Deviation 16.86
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 40; n= 61, 66	-0.3 International Unit per Liter (IU/L)	Standard Deviation 19.75
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 44; n= 61, 66	-2.7 International Unit per Liter (IU/L)	Standard Deviation 15.25
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 48; n= 61, 64	-3.0 International Unit per Liter (IU/L)	Standard Deviation 16.51
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	GGT; Week 60; n= 60, 65	-5.6 International Unit per Liter (IU/L)	Standard Deviation 15.37
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Absolute Lactate dehydro; Baseline; n= 68, 68	179.6 International Unit per Liter (IU/L)	Standard Deviation 38.88
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 4; n= 68, 68	-2.3 International Unit per Liter (IU/L)	Standard Deviation 27.8
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 8; n= 67, 66	-5.3 International Unit per Liter (IU/L)	Standard Deviation 24.46
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 12; n= 65, 68	-7.7 International Unit per Liter (IU/L)	Standard Deviation 25.56
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 16; n= 65, 68	-10.6 International Unit per Liter (IU/L)	Standard Deviation 26.12
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 20; n= 63, 68	-13.7 International Unit per Liter (IU/L)	Standard Deviation 25.79
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 24; n= 63, 66	-13.5 International Unit per Liter (IU/L)	Standard Deviation 26.99
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 28; n= 61, 66	-15.9 International Unit per Liter (IU/L)	Standard Deviation 30.44
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 32; n= 61, 67	-17.1 International Unit per Liter (IU/L)	Standard Deviation 24.88
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 36; n= 60, 67	-16.2 International Unit per Liter (IU/L)	Standard Deviation 30.54
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 40; n= 61, 66	-13.5 International Unit per Liter (IU/L)	Standard Deviation 36.31
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 44; n= 61, 66	-17.0 International Unit per Liter (IU/L)	Standard Deviation 31.37
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 48; n= 61, 64	-19.0 International Unit per Liter (IU/L)	Standard Deviation 30.66
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 52; n= 60, 65	-17.8 International Unit per Liter (IU/L)	Standard Deviation 33.45
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	Lactate dehydro; Week 56; n= 61, 63	-16.0 International Unit per Liter (IU/L)	Standard Deviation 30.87
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels	ALT; Week 36; n= 60, 67	-3.0 International Unit per Liter (IU/L)	Standard Deviation 11.66

Secondary

Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels

Blood samples were collected to evaluate change from Baseline in albumin and protein levels values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 48; n= 61, 64	-0.4 gram per liter (g/L)	Standard Deviation 2.74
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 60; n= 60, 65	-0.4 gram per liter (g/L)	Standard Deviation 5.88
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 52; n= 60, 65	-0.5 gram per liter (g/L)	Standard Deviation 2.45
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 16; n= 65, 68	-0.6 gram per liter (g/L)	Standard Deviation 2.57
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 56; n= 61, 63	-0.7 gram per liter (g/L)	Standard Deviation 2.84
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 32; n= 61, 67	-0.4 gram per liter (g/L)	Standard Deviation 2.71
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 60; n= 60, 65	-0.9 gram per liter (g/L)	Standard Deviation 2.55
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 20; n= 63, 68	-0.1 gram per liter (g/L)	Standard Deviation 2.35
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Absolute Protein; Baseline; n= 68, 68	67.7 gram per liter (g/L)	Standard Deviation 4.26
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Absolute Albumin; Baseline; n= 68, 68	43.4 gram per liter (g/L)	Standard Deviation 2.45
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 4; n= 68, 68	-0.8 gram per liter (g/L)	Standard Deviation 3
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 24; n= 63, 66	0.0 gram per liter (g/L)	Standard Deviation 2.8
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 12; n= 65, 68	-0.6 gram per liter (g/L)	Standard Deviation 3.57
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 8; n= 67, 66	-1.5 gram per liter (g/L)	Standard Deviation 2.97
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 16; n= 65, 68	-0.3 gram per liter (g/L)	Standard Deviation 3.56
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 28; n= 62, 66	-0.2 gram per liter (g/L)	Standard Deviation 2.67
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 24; n= 63, 66	0.2 gram per liter (g/L)	Standard Deviation 3.99
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 4; n= 68, 68	-0.6 gram per liter (g/L)	Standard Deviation 2.25
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 28; n= 62, 66	-0.2 gram per liter (g/L)	Standard Deviation 4.13
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 20; n= 63, 68	0.0 gram per liter (g/L)	Standard Deviation 3.21
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 32; n= 61, 67	-0.5 gram per liter (g/L)	Standard Deviation 4.09
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 36; n= 60, 67	-0.1 gram per liter (g/L)	Standard Deviation 2.58
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 36; n= 60, 67	-0.2 gram per liter (g/L)	Standard Deviation 3.82
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 8; n= 67, 66	-0.8 gram per liter (g/L)	Standard Deviation 2.16
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 40; n= 61, 66	-0.4 gram per liter (g/L)	Standard Deviation 3.48
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 40; n= 61, 66	-0.2 gram per liter (g/L)	Standard Deviation 2.98
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 44; n= 61, 66	0.4 gram per liter (g/L)	Standard Deviation 4.43
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; week 56; n= 61, 63	-0.1 gram per liter (g/L)	Standard Deviation 4.77
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 48; n= 61, 64	-0.5 gram per liter (g/L)	Standard Deviation 3.94
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 44; n= 61, 66	0.3 gram per liter (g/L)	Standard Deviation 2.95
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 52; n= 60, 65	-0.3 gram per liter (g/L)	Standard Deviation 3.75
Placebo	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 12; n= 65, 68	-0.2 gram per liter (g/L)	Standard Deviation 2.47
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 60; n= 60, 65	-0.7 gram per liter (g/L)	Standard Deviation 4.17
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 8; n= 67, 66	-0.9 gram per liter (g/L)	Standard Deviation 3.6
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 20; n= 63, 68	0.1 gram per liter (g/L)	Standard Deviation 4.28
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 52; n= 60, 65	-0.4 gram per liter (g/L)	Standard Deviation 4.08
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Absolute Albumin; Baseline; n= 68, 68	43.5 gram per liter (g/L)	Standard Deviation 3.01
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 4; n= 68, 68	-0.1 gram per liter (g/L)	Standard Deviation 2.16
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 8; n= 67, 66	-0.6 gram per liter (g/L)	Standard Deviation 2.72
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 12; n= 65, 68	-0.4 gram per liter (g/L)	Standard Deviation 2.64
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 16; n= 65, 68	-0.6 gram per liter (g/L)	Standard Deviation 2.54
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 20; n= 63, 68	-0.2 gram per liter (g/L)	Standard Deviation 2.92
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 24; n= 63, 66	0.1 gram per liter (g/L)	Standard Deviation 2.72
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 28; n= 62, 66	0.1 gram per liter (g/L)	Standard Deviation 2.67
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 32; n= 61, 67	-0.1 gram per liter (g/L)	Standard Deviation 2.69
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 36; n= 60, 67	0.3 gram per liter (g/L)	Standard Deviation 3.01
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 40; n= 61, 66	0.2 gram per liter (g/L)	Standard Deviation 2.82
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 44; n= 61, 66	-0.3 gram per liter (g/L)	Standard Deviation 2.87
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 48; n= 61, 64	-0.3 gram per liter (g/L)	Standard Deviation 2.77
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 52; n= 60, 65	-0.3 gram per liter (g/L)	Standard Deviation 3.1
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 56; n= 61, 63	-0.5 gram per liter (g/L)	Standard Deviation 2.88
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Albumin; Week 60; n= 60, 65	-0.7 gram per liter (g/L)	Standard Deviation 3.04
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Absolute Protein; Baseline; n= 68, 68	67.3 gram per liter (g/L)	Standard Deviation 4.46
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 4; n= 68, 68	-0.5 gram per liter (g/L)	Standard Deviation 3.19
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 12; n= 65, 68	-0.6 gram per liter (g/L)	Standard Deviation 3.3
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 16; n= 65, 68	-0.8 gram per liter (g/L)	Standard Deviation 3.93
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 24; n= 63, 66	0.0 gram per liter (g/L)	Standard Deviation 3.96
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 28; n= 62, 66	-0.1 gram per liter (g/L)	Standard Deviation 3.59
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 32; n= 61, 67	-0.4 gram per liter (g/L)	Standard Deviation 3.91
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 36; n= 60, 67	0.2 gram per liter (g/L)	Standard Deviation 4.45
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 40; n= 61, 66	0.1 gram per liter (g/L)	Standard Deviation 3.98
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 44; n= 61, 66	-0.6 gram per liter (g/L)	Standard Deviation 4.19
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; Week 48; n= 61, 64	-0.5 gram per liter (g/L)	Standard Deviation 4.29
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels	Protein; week 56; n= 61, 63	-0.5 gram per liter (g/L)	Standard Deviation 4.21

Secondary

Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels

Blood samples were collected to evaluate change from Baseline in direct, indirect and total bilirubin and creatinine values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 40; n= 61, 66	-0.2 micromole per liter (µmol/L)	Standard Deviation 3.22
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 52; n= 60, 65	-0.2 micromole per liter (µmol/L)	Standard Deviation 2.84
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 48; n= 61, 64	-0.2 micromole per liter (µmol/L)	Standard Deviation 2.59
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 40; n= 61, 66	-0.1 micromole per liter (µmol/L)	Standard Deviation 2.56
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 52; n= 60, 65	-0.1 micromole per liter (µmol/L)	Standard Deviation 3.41
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 24; n= 63, 66	-0.3 micromole per liter (µmol/L)	Standard Deviation 3.36
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 56; n= 61, 63	-0.8 micromole per liter (µmol/L)	Standard Deviation 3.17
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 44; n= 61, 66	-0.1 micromole per liter (µmol/L)	Standard Deviation 2.19
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 4; n= 68, 68	0.69 micromole per liter (µmol/L)	Standard Deviation 7.195
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 56; n= 61, 63	-0.9 micromole per liter (µmol/L)	Standard Deviation 2.72
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 12; n= 65, 68	1.50 micromole per liter (µmol/L)	Standard Deviation 9.029
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 56; n= 61, 63	0.1 micromole per liter (µmol/L)	Standard Deviation 1.08
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Creatinine; Baseline; n= 68, 68	75.49 micromole per liter (µmol/L)	Standard Deviation 12.878
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 20; n= 63, 68	1.73 micromole per liter (µmol/L)	Standard Deviation 6.916
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 60; n= 60, 65	0.1 micromole per liter (µmol/L)	Standard Deviation 1.1
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 24; n= 63, 66	0.74 micromole per liter (µmol/L)	Standard Deviation 7.775
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 60; n= 60, 65	-0.6 micromole per liter (µmol/L)	Standard Deviation 2.64
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 28; n= 62, 66	0.96 micromole per liter (µmol/L)	Standard Deviation 7.504
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Indirect bilirubin; Baseline; n= 68, 68	7.7 micromole per liter (µmol/L)	Standard Deviation 5.09
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 32; n= 61, 67	1.89 micromole per liter (µmol/L)	Standard Deviation 9.809
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 44; n= 61, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 2.5
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 36; n= 60, 67	1.42 micromole per liter (µmol/L)	Standard Deviation 6.957
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 4; n= 68, 68	-0.8 micromole per liter (µmol/L)	Standard Deviation 3.68
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 40; n= 61, 66	1.16 micromole per liter (µmol/L)	Standard Deviation 8.253
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 16; n= 65, 68	-0.9 micromole per liter (µmol/L)	Standard Deviation 3.67
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 44; n= 61, 66	2.14 micromole per liter (µmol/L)	Standard Deviation 8.991
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 8; n= 67, 66	-1.2 micromole per liter (µmol/L)	Standard Deviation 3.86
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 48; n= 61, 64	1.53 micromole per liter (µmol/L)	Standard Deviation 7.972
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 28; n= 62, 66	-0.8 micromole per liter (µmol/L)	Standard Deviation 3.13
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 52; n= 60, 65	0.52 micromole per liter (µmol/L)	Standard Deviation 7.719
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 12; n= 65, 68	-0.3 micromole per liter (µmol/L)	Standard Deviation 2.61
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 56; n= 61, 63	1.39 micromole per liter (µmol/L)	Standard Deviation 7.367
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 20; n= 63, 68	-0.5 micromole per liter (µmol/L)	Standard Deviation 2.37
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 60; n= 60, 65	0.34 micromole per liter (µmol/L)	Standard Deviation 7.014
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Total bilirubin; Baseline; n= 68, 68	9.8 micromole per liter (µmol/L)	Standard Deviation 6.14
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Direct bilirubin; Baseline; n= 68, 68	2.1 micromole per liter (µmol/L)	Standard Deviation 1.33
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 8; n= 67, 66	1.87 micromole per liter (µmol/L)	Standard Deviation 7.505
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 4; n= 68, 68	0.0 micromole per liter (µmol/L)	Standard Deviation 1.06
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; week 4; n= 68, 68	-0.9 micromole per liter (µmol/L)	Standard Deviation 4.02
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 8; n= 67, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 1.01
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 16; n= 65, 68	1.53 micromole per liter (µmol/L)	Standard Deviation 10.012
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 12; n= 65, 68	0.0 micromole per liter (µmol/L)	Standard Deviation 0.97
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 8; n= 67, 66	-1.2 micromole per liter (µmol/L)	Standard Deviation 4.38
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 16; n= 65, 68	-0.2 micromole per liter (µmol/L)	Standard Deviation 0.96
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 28; n= 62, 66	-0.7 micromole per liter (µmol/L)	Standard Deviation 2.6
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 20; n= 63, 68	0.0 micromole per liter (µmol/L)	Standard Deviation 0.86
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 12; n= 65, 68	-0.3 micromole per liter (µmol/L)	Standard Deviation 3.01
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 24; n= 63, 66	0.1 micromole per liter (µmol/L)	Standard Deviation 0.9
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 24; n= 63, 66	-0.4 micromole per liter (µmol/L)	Standard Deviation 2.94
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 28; n= 62, 66	-0.1 micromole per liter (µmol/L)	Standard Deviation 1.2
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 16; n= 65, 68	-1.1 micromole per liter (µmol/L)	Standard Deviation 4.15
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 32; n= 61, 67	-0.2 micromole per liter (µmol/L)	Standard Deviation 0.99
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 32; n= 61, 66	-0.9 micromole per liter (µmol/L)	Standard Deviation 2.48
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 36; n= 60, 67	-0.1 micromole per liter (µmol/L)	Standard Deviation 1.11
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 20; n= 63, 68	-0.5 micromole per liter (µmol/L)	Standard Deviation 2.9
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 40; n= 61, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 1.11
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 32; n= 61, 67	-1.1 micromole per liter (µmol/L)	Standard Deviation 3.07
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 44; n= 61, 66	0.1 micromole per liter (µmol/L)	Standard Deviation 0.93
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 60; n= 60, 65	-0.5 micromole per liter (µmol/L)	Standard Deviation 3.21
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 48; n= 61, 64	0.1 micromole per liter (µmol/L)	Standard Deviation 0.99
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 36; n= 60, 67	-0.7 micromole per liter (µmol/L)	Standard Deviation 3.39
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 52; n= 60, 65	0.1 micromole per liter (µmol/L)	Standard Deviation 1.05
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 36; n= 60, 67	-0.6 micromole per liter (µmol/L)	Standard Deviation 2.77
Placebo	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 48; n= 61, 64	-0.3 micromole per liter (µmol/L)	Standard Deviation 2.19
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 24; n= 63, 66	0.06 micromole per liter (µmol/L)	Standard Deviation 6.538
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 24; n= 63, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 2.71
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 28; n= 62, 66	0.3 micromole per liter (µmol/L)	Standard Deviation 4.43
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 44; n= 61, 66	0.1 micromole per liter (µmol/L)	Standard Deviation 3.64
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 60; n= 60, 65	0.0 micromole per liter (µmol/L)	Standard Deviation 3.42
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Creatinine; Baseline; n= 68, 68	73.00 micromole per liter (µmol/L)	Standard Deviation 12.289
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 4; n= 68, 68	2.09 micromole per liter (µmol/L)	Standard Deviation 5.533
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 48; n= 61, 64	-0.1 micromole per liter (µmol/L)	Standard Deviation 3.13
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 52; n= 60, 65	0.5 micromole per liter (µmol/L)	Standard Deviation 3.32
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 56; n= 61, 63	0.4 micromole per liter (µmol/L)	Standard Deviation 2.64
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 60; n= 60, 65	-0.1 micromole per liter (µmol/L)	Standard Deviation 2.81
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 16; n= 65, 68	0.1 micromole per liter (µmol/L)	Standard Deviation 3.37
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 20; n= 63, 68	0.2 micromole per liter (µmol/L)	Standard Deviation 3
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 24; n= 63, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 2.37
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 28; n= 62, 66	0.1 micromole per liter (µmol/L)	Standard Deviation 3.71
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 32; n= 61, 66	-0.2 micromole per liter (µmol/L)	Standard Deviation 3.02
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 36; n= 60, 67	0.0 micromole per liter (µmol/L)	Standard Deviation 3.3
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 40; n= 61, 66	-0.2 micromole per liter (µmol/L)	Standard Deviation 3.16
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 44; n= 61, 66	0.1 micromole per liter (µmol/L)	Standard Deviation 2.99
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 56; n= 61, 63	0.1 micromole per liter (µmol/L)	Standard Deviation 1.06
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 60; n= 60, 65	0.1 micromole per liter (µmol/L)	Standard Deviation 1.07
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Indirect bilirubin; Baseline; n= 68, 68	6.9 micromole per liter (µmol/L)	Standard Deviation 3.38
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 4; n= 68, 68	0.0 micromole per liter (µmol/L)	Standard Deviation 3.06
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 8; n= 67, 66	-0.1 micromole per liter (µmol/L)	Standard Deviation 2.94
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Indirect bilirubin; Week 12; n= 65, 68	0.1 micromole per liter (µmol/L)	Standard Deviation 2.79
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Total bilirubin; Baseline; n= 68, 68	8.8 micromole per liter (µmol/L)	Standard Deviation 4.1
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; week 4; n= 68, 68	0.1 micromole per liter (µmol/L)	Standard Deviation 3.48
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 8; n= 67, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 3.5
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 12; n= 65, 68	0.1 micromole per liter (µmol/L)	Standard Deviation 3.27
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 16; n= 65, 68	0.0 micromole per liter (µmol/L)	Standard Deviation 4.14
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 32; n= 61, 67	-0.1 micromole per liter (µmol/L)	Standard Deviation 3.63
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 36; n= 60, 67	0.1 micromole per liter (µmol/L)	Standard Deviation 4.09
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 40; n= 61, 66	-0.3 micromole per liter (µmol/L)	Standard Deviation 3.78
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 48; n= 61, 64	-0.1 micromole per liter (µmol/L)	Standard Deviation 3.77
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 52; n= 60, 65	0.7 micromole per liter (µmol/L)	Standard Deviation 3.92
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 56; n= 61, 63	0.5 micromole per liter (µmol/L)	Standard Deviation 3.24
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 8; n= 67, 66	1.15 micromole per liter (µmol/L)	Standard Deviation 6.737
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 12; n= 65, 68	0.34 micromole per liter (µmol/L)	Standard Deviation 7.006
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 16; n= 65, 68	2.72 micromole per liter (µmol/L)	Standard Deviation 6.702
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 20; n= 63, 68	2.60 micromole per liter (µmol/L)	Standard Deviation 7.739
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Total bilirubin; Week 20; n= 63, 68	0.3 micromole per liter (µmol/L)	Standard Deviation 3.57
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 28; n= 62, 66	1.02 micromole per liter (µmol/L)	Standard Deviation 7.764
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 32; n= 61, 67	1.85 micromole per liter (µmol/L)	Standard Deviation 8.589
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 36; n= 60, 67	0.40 micromole per liter (µmol/L)	Standard Deviation 7.839
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 40; n= 61, 66	0.34 micromole per liter (µmol/L)	Standard Deviation 8.119
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 44; n= 61, 66	0.04 micromole per liter (µmol/L)	Standard Deviation 9.07
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 48; n= 61, 64	-2.25 micromole per liter (µmol/L)	Standard Deviation 7.398
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 52; n= 60, 65	-1.35 micromole per liter (µmol/L)	Standard Deviation 7.182
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 56; n= 61, 63	-0.30 micromole per liter (µmol/L)	Standard Deviation 8.695
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Creatinine; Week 60; n= 60, 65	-1.22 micromole per liter (µmol/L)	Standard Deviation 10.896
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Absolute Direct bilirubin; Baseline; n= 68, 68	1.9 micromole per liter (µmol/L)	Standard Deviation 0.98
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 4; n= 68, 68	0.0 micromole per liter (µmol/L)	Standard Deviation 0.84
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 8; n= 67, 66	0.1 micromole per liter (µmol/L)	Standard Deviation 0.96
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 12; n= 65, 68	0.0 micromole per liter (µmol/L)	Standard Deviation 1.04
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 16; n= 65, 68	-0.1 micromole per liter (µmol/L)	Standard Deviation 1.2
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 20; n= 63, 68	0.1 micromole per liter (µmol/L)	Standard Deviation 1.03
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 24; n= 63, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 0.88
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 28; n= 62, 66	0.2 micromole per liter (µmol/L)	Standard Deviation 1.15
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 32; n= 61, 67	0.1 micromole per liter (µmol/L)	Standard Deviation 0.99
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 36; n= 60, 67	0.1 micromole per liter (µmol/L)	Standard Deviation 1.17
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 40; n= 61, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 0.94
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 44; n= 61, 66	0.0 micromole per liter (µmol/L)	Standard Deviation 1.12
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 48; n= 61, 64	0.0 micromole per liter (µmol/L)	Standard Deviation 1.17
Mepolizumab 300mg	Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels	Direct bilirubin; Week 52; n= 60, 65	0.2 micromole per liter (µmol/L)	Standard Deviation 1.06

Secondary

Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels

Blood samples were collected to evaluate change from Baseline in basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelet values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 32; n= 61, 66	0.244 10^9 cells/L	Standard Deviation 0.9633
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 20; n= 61, 66	0.132 10^9 cells/L	Standard Deviation 0.2684
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 24; n= 61, 66	0.061 10^9 cells/L	Standard Deviation 0.229
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 28; n= 62, 65	0.107 10^9 cells/L	Standard Deviation 0.2363
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 32; n= 61, 66	0.108 10^9 cells/L	Standard Deviation 0.2839
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 36; n= 60, 66	0.089 10^9 cells/L	Standard Deviation 0.2992
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 40; n= 61, 65	0.084 10^9 cells/L	Standard Deviation 0.2495
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 44; n= 59, 61	0.090 10^9 cells/L	Standard Deviation 0.2494
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 48; n= 59, 64	0.078 10^9 cells/L	Standard Deviation 0.2261
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 52; n= 60, 64	0.075 10^9 cells/L	Standard Deviation 0.2407
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 56; n= 59, 61	0.051 10^9 cells/L	Standard Deviation 0.2104
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 60; n= 58, 64	0.052 10^9 cells/L	Standard Deviation 0.26
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Neutrophils; Baseline; n= 68, 68	7.500 10^9 cells/L	Standard Deviation 2.7424
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 4; n= 66, 66	-0.124 10^9 cells/L	Standard Deviation 2.617
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 8; n= 65, 66	-0.572 10^9 cells/L	Standard Deviation 2.6791
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 12; n= 63, 65	-0.797 10^9 cells/L	Standard Deviation 2.2948
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 16; n= 64, 68	-0.222 10^9 cells/L	Standard Deviation 2.7666
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 20; n= 61, 66	-0.560 10^9 cells/L	Standard Deviation 2.3679
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 24; n= 61, 66	-0.980 10^9 cells/L	Standard Deviation 2.3151
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 28; n= 62, 65	-0.555 10^9 cells/L	Standard Deviation 2.3719
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 32; n= 61, 66	-0.762 10^9 cells/L	Standard Deviation 2.4952
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 36; n= 60, 66	-0.509 10^9 cells/L	Standard Deviation 2.8231
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 40; n= 61, 65	-0.009 10^9 cells/L	Standard Deviation 3.0467
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Basophils; Baselin; n= 68, 68	0.030 10^9 cells/L	Standard Deviation 0.0253
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 4; n= 66, 66	-0.002 10^9 cells/L	Standard Deviation 0.0302
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 8; n= 65, 66	0.005 10^9 cells/L	Standard Deviation 0.0285
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 12; n= 63, 65	0.007 10^9 cells/L	Standard Deviation 0.0351
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 16; n= 64, 68	0.005 10^9 cells/L	Standard Deviation 0.0333
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 20; n= 61, 66	0.005 10^9 cells/L	Standard Deviation 0.0338
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 24; n= 61, 66	0.004 10^9 cells/L	Standard Deviation 0.0341
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 28; n= 62, 65	0.006 10^9 cells/L	Standard Deviation 0.0411
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 32; n= 61, 66	0.010 10^9 cells/L	Standard Deviation 0.0467
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 36; n= 60, 66	0.009 10^9 cells/L	Standard Deviation 0.0321
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 40; n= 61, 65	0.005 10^9 cells/L	Standard Deviation 0.0357
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 44; n= 59, 61	0.008 10^9 cells/L	Standard Deviation 0.0328
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 48; n= 59, 64	0.003 10^9 cells/L	Standard Deviation 0.0408
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 52; n= 60, 64	0.004 10^9 cells/L	Standard Deviation 0.0289
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 56; n= 59, 61	0.009 10^9 cells/L	Standard Deviation 0.0381
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 60; n= 58, 64	0.002 10^9 cells/L	Standard Deviation 0.0316
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Eosinophils; Baseline; n= 68, 68	0.362 10^9 cells/L	Standard Deviation 0.5835
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 4; n= 66, 66	-0.054 10^9 cells/L	Standard Deviation 0.3309
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 8; n= 65, 66	0.103 10^9 cells/L	Standard Deviation 0.2921
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 12; n= 63, 65	0.027 10^9 cells/L	Standard Deviation 0.3515
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 16; n= 64, 68	0.058 10^9 cells/L	Standard Deviation 0.4092
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 20; n= 61, 66	0.162 10^9 cells/L	Standard Deviation 0.59
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 24; n= 61, 66	0.136 10^9 cells/L	Standard Deviation 0.4044
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 44; n= 59, 61	-0.020 10^9 cells/L	Standard Deviation 3.3497
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 48; n= 59, 64	-0.403 10^9 cells/L	Standard Deviation 3.2656
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 52; n= 60, 64	-0.391 10^9 cells/L	Standard Deviation 3.4463
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 56; n= 59, 61	-0.381 10^9 cells/L	Standard Deviation 3.4297
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 60; n= 58, 64	-0.048 10^9 cells/L	Standard Deviation 3.5724
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Platelets; Baseline; n= 68, 68	259.8 10^9 cells/L	Standard Deviation 61.16
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 4; n= 66, 67	4.5 10^9 cells/L	Standard Deviation 38.14
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 8; n= 66, 66	5.0 10^9 cells/L	Standard Deviation 43.97
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 12; n= 63, 65	3.1 10^9 cells/L	Standard Deviation 50.6
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 16; n= 64, 68	15.4 10^9 cells/L	Standard Deviation 71.2
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 20; n= 61, 68	12.3 10^9 cells/L	Standard Deviation 49.92
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 24; n= 62, 65	10.9 10^9 cells/L	Standard Deviation 50.38
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 28; n= 62, 66	13.3 10^9 cells/L	Standard Deviation 55.12
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 32; n= 61, 67	12.1 10^9 cells/L	Standard Deviation 45.36
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 36; n= 60, 66	9.3 10^9 cells/L	Standard Deviation 42.64
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 28; n= 62, 65	0.172 10^9 cells/L	Standard Deviation 0.4365
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 32; n= 61, 66	0.079 10^9 cells/L	Standard Deviation 0.3759
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 36; n= 60, 66	0.086 10^9 cells/L	Standard Deviation 0.3758
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 40; n= 61, 65	0.022 10^9 cells/L	Standard Deviation 0.4448
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 44; n= 59, 61	0.051 10^9 cells/L	Standard Deviation 0.4472
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 48; n= 59, 64	0.109 10^9 cells/L	Standard Deviation 0.3873
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 52; n= 60, 64	0.055 10^9 cells/L	Standard Deviation 0.3764
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 56; n= 59, 61	0.071 10^9 cells/L	Standard Deviation 0.4137
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 60; n= 58, 64	0.111 10^9 cells/L	Standard Deviation 0.4666
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Leukocytes; Baseline; n= 68, 68	9.91 10^9 cells/L	Standard Deviation 2.714
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 4; 66, 66	-0.11 10^9 cells/L	Standard Deviation 2.109
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 8; n= 65, 66	-0.18 10^9 cells/L	Standard Deviation 2.562
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 12; n= 63, 65	-0.53 10^9 cells/L	Standard Deviation 1.765
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 40; n= 61, 65	14.7 10^9 cells/L	Standard Deviation 45.63
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 44; n= 60, 63	19.3 10^9 cells/L	Standard Deviation 48.88
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 48; n= 59, 64	14.2 10^9 cells/L	Standard Deviation 53.93
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 52; n= 60, 64	14.7 10^9 cells/L	Standard Deviation 48.19
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 56; n= 59, 61	20.3 10^9 cells/L	Standard Deviation 47.35
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 60; n= 59, 64	13.0 10^9 cells/L	Standard Deviation 50.07
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; ; Week 16; n= 64, 68	0.01 10^9 cells/L	Standard Deviation 2.567
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 20; n= 61, 66	-0.13 10^9 cells/L	Standard Deviation 2.269
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 24; n= 61, 66	-0.73 10^9 cells/L	Standard Deviation 2.11
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 28; n= 62, 65	-0.01 10^9 cells/L	Standard Deviation 2.297
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; week 32; n= 61, 66	-0.33 10^9 cells/L	Standard Deviation 2.218
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 36; n= 60, 66	-0.17 10^9 cells/L	Standard Deviation 2.501
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 40; n= 61, 65	0.17 10^9 cells/L	Standard Deviation 2.912
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 44; n= 59, 61	0.25 10^9 cells/L	Standard Deviation 3.166
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 48; n= 59, 64	-0.10 10^9 cells/L	Standard Deviation 3.092
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 52; n= 60, 64	-0.12 10^9 cells/L	Standard Deviation 3.114
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 56; n= 59, 61	-0.05 10^9 cells/L	Standard Deviation 3.357
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 60; n= 58, 64	0.19 10^9 cells/L	Standard Deviation 3.533
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Lymphocytes; Baseline; n= 68, 68	1.638 10^9 cells/L	Standard Deviation 0.9375
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 4; n= 66, 66	0.031 10^9 cells/L	Standard Deviation 0.899
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 8; n= 65, 66	0.245 10^9 cells/L	Standard Deviation 0.8804
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 12; n= 63, 65	0.160 10^9 cells/L	Standard Deviation 0.9043
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 16; n= 64, 68	0.078 10^9 cells/L	Standard Deviation 1.0337
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 20; n= 61, 66	0.137 10^9 cells/L	Standard Deviation 0.7984
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 24; n= 61, 66	0.056 10^9 cells/L	Standard Deviation 0.8778
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 28; n= 62, 65	0.261 10^9 cells/L	Standard Deviation 1.0966
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 36; n= 60, 66	0.156 10^9 cells/L	Standard Deviation 1.0399
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 40; n= 61, 65	0.064 10^9 cells/L	Standard Deviation 1.0537
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 44; n= 59, 61	0.130 10^9 cells/L	Standard Deviation 0.8773
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 48; n=59, 64	0.106 10^9 cells/L	Standard Deviation 0.8396
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 52; n= 60, 64	0.144 10^9 cells/L	Standard Deviation 0.9262
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 56; n= 59, 61	0.200 10^9 cells/L	Standard Deviation 0.8356
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 60; n= 58, 64	0.076 10^9 cells/L	Standard Deviation 0.8821
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Monocytes; Baseline; n= 68, 68	0.377 10^9 cells/L	Standard Deviation 0.2126
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; week 4; n= 66, 66	0.038 10^9 cells/L	Standard Deviation 0.2444
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 8; n= 65, 66	0.052 10^9 cells/L	Standard Deviation 0.2271
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 12; n= 63, 65	0.077 10^9 cells/L	Standard Deviation 0.2468
Placebo	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 16; n= 64, 68	0.086 10^9 cells/L	Standard Deviation 0.279
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 52; n= 60, 64	0.031 10^9 cells/L	Standard Deviation 0.6244
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 32; n= 61, 66	0.057 10^9 cells/L	Standard Deviation 0.2069
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 16; n= 64, 68	0.031 10^9 cells/L	Standard Deviation 0.2157
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 20; n= 61, 68	6.1 10^9 cells/L	Standard Deviation 52.76
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 20; n= 61, 66	0.030 10^9 cells/L	Standard Deviation 0.1967
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; week 32; n= 61, 66	-1.54 10^9 cells/L	Standard Deviation 2.725
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 24; n= 61, 66	0.013 10^9 cells/L	Standard Deviation 0.2412
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 24; n= 62, 65	-4.2 10^9 cells/L	Standard Deviation 40.07
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 28; n= 62, 65	0.035 10^9 cells/L	Standard Deviation 0.235
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 24; n= 61, 66	0.011 10^9 cells/L	Standard Deviation 0.8077
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 28; n= 62, 66	5.4 10^9 cells/L	Standard Deviation 41.57
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 36; n= 60, 66	0.072 10^9 cells/L	Standard Deviation 0.2416
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 36; n= 60, 66	-1.37 10^9 cells/L	Standard Deviation 2.578
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 40; n= 61, 65	0.050 10^9 cells/L	Standard Deviation 0.2096
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 32; n= 61, 67	0.7 10^9 cells/L	Standard Deviation 43.85
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 44; n= 59, 61	0.077 10^9 cells/L	Standard Deviation 0.2176
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 8; n= 65, 66	0.039 10^9 cells/L	Standard Deviation 0.1988
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 48; n= 59, 64	0.025 10^9 cells/L	Standard Deviation 0.2235
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 36; n= 60, 66	0.6 10^9 cells/L	Standard Deviation 37.87
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 52; n= 60, 64	0.024 10^9 cells/L	Standard Deviation 0.2098
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 40; n= 61, 65	-1.28 10^9 cells/L	Standard Deviation 3.284
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 56; n= 59, 61	0.037 10^9 cells/L	Standard Deviation 0.2303
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 28; n= 62, 65	-0.360 10^9 cells/L	Standard Deviation 0.8258
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 60; n= 58, 64	0.001 10^9 cells/L	Standard Deviation 0.2165
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 28; n= 62, 65	0.004 10^9 cells/L	Standard Deviation 0.7328
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Neutrophils; Baseline; n= 68, 68	7.198 10^9 cells/L	Standard Deviation 2.9732
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 32; n= 61, 66	-0.347 10^9 cells/L	Standard Deviation 0.831
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 4; n= 66, 66	-0.583 10^9 cells/L	Standard Deviation 2.2703
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 44; n= 59, 61	-1.57 10^9 cells/L	Standard Deviation 2.198
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 8; n= 65, 66	-0.443 10^9 cells/L	Standard Deviation 2.56476
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 36; n= 60, 66	-0.347 10^9 cells/L	Standard Deviation 0.8388
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 12; n= 63, 65	-0.799 10^9 cells/L	Standard Deviation 2.6278
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 32; n= 61, 66	0.031 10^9 cells/L	Standard Deviation 0.7986
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 16; n= 64, 68	-0.914 10^9 cells/L	Standard Deviation 2.6034
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 40; n= 61, 65	-0.358 10^9 cells/L	Standard Deviation 0.8396
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 20; n= 61, 66	-1.243 10^9 cells/L	Standard Deviation 2.6857
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 48; n= 59, 64	-1.46 10^9 cells/L	Standard Deviation 2.546
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 24; n= 61, 66	-1.120 10^9 cells/L	Standard Deviation 2.8349
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 44; n= 59, 61	-0.365 10^9 cells/L	Standard Deviation 0.8604
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 28; n= 62, 65	-1.335 10^9 cells/L	Standard Deviation 2.9428
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 56; n= 59, 61	0.128 10^9 cells/L	Standard Deviation 0.7824
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 32; n= 61, 66	-1.286 10^9 cells/L	Standard Deviation 2.6995
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 48; n= 59, 64	-0.364 10^9 cells/L	Standard Deviation 0.854
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 36; n= 60, 66	-1.131 10^9 cells/L	Standard Deviation 2.4261
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 52; n= 60, 64	-1.50 10^9 cells/L	Standard Deviation 2.521
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 52; n= 60, 64	-0.341 10^9 cells/L	Standard Deviation 0.8456
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Basophils; Baselin; n= 68, 68	0.028 10^9 cells/L	Standard Deviation 0.0236
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 36; n= 60, 66	0.031 10^9 cells/L	Standard Deviation 0.5939
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 4; n= 66, 66	-0.007 10^9 cells/L	Standard Deviation 0.0282
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 56; n= 59, 61	-0.351 10^9 cells/L	Standard Deviation 0.8624
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 8; n= 65, 66	-0.002 10^9 cells/L	Standard Deviation 0.0261
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 56; n= 59, 61	-1.50 10^9 cells/L	Standard Deviation 2.84
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 12; n= 63, 65	-0.007 10^9 cells/L	Standard Deviation 0.0222
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 60; n= 58, 64	-0.302 10^9 cells/L	Standard Deviation 0.8352
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 16; n= 64, 68	-0.004 10^9 cells/L	Standard Deviation 0.0295
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; week 4; n= 66, 66	0.014 10^9 cells/L	Standard Deviation 0.2127
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 20; n= 61, 66	-0.002 10^9 cells/L	Standard Deviation 0.0287
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Leukocytes; Baseline; n= 68, 68	9.54 10^9 cells/L	Standard Deviation 3.13
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 24; n= 61, 66	-0.002 10^9 cells/L	Standard Deviation 0.0328
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 60; n= 58, 64	-1.20 10^9 cells/L	Standard Deviation 2.396
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 28; n= 62, 65	-0.005 10^9 cells/L	Standard Deviation 0.0297
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 4; 66, 66	-0.77 10^9 cells/L	Standard Deviation 2.356
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 32; n= 61, 66	0.002 10^9 cells/L	Standard Deviation 0.0355
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 40; n= 61, 65	0.037 10^9 cells/L	Standard Deviation 0.6391
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 36; n= 60, 66	0.005 10^9 cells/L	Standard Deviation 0.0424
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 8; n= 65, 66	-0.83 10^9 cells/L	Standard Deviation 2.511
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 40; n= 61, 65	-0.002 10^9 cells/L	Standard Deviation 0.0356
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Lymphocytes; Baseline; n= 68, 68	1.508 10^9 cells/L	Standard Deviation 0.823
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 44; n= 59, 61	0.000 10^9 cells/L	Standard Deviation 0.0296
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 60; n= 58, 64	-0.101 10^9 cells/L	Standard Deviation 0.6848
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 48; n= 59, 64	-0.004 10^9 cells/L	Standard Deviation 0.03
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 40; n= 61, 65	2.0 10^9 cells/L	Standard Deviation 42.12
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 52; n= 60, 64	-0.003 10^9 cells/L	Standard Deviation 0.0284
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 4; n= 66, 66	0.145 10^9 cells/L	Standard Deviation 0.7485
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 56; n= 59, 61	-0.003 10^9 cells/L	Standard Deviation 0.0286
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 44; n= 60, 63	4.9 10^9 cells/L	Standard Deviation 40.27
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Basophils; Week 60; n= 58, 64	-0.006 10^9 cells/L	Standard Deviation 0.0248
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 44; n= 59, 61	0.059 10^9 cells/L	Standard Deviation 0.6471
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Eosinophils; Baseline; n= 68, 68	0.398 10^9 cells/L	Standard Deviation 0.8415
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 48; n= 59, 64	5.4 10^9 cells/L	Standard Deviation 44.8
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 4; n= 66, 66	-0.339 10^9 cells/L	Standard Deviation 0.6794
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 8; n= 65, 66	-0.048 10^9 cells/L	Standard Deviation 0.6388
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 8; n= 65, 66	-0.370 10^9 cells/L	Standard Deviation 0.8092
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 52; n= 60, 64	-3.7 10^9 cells/L	Standard Deviation 46.34
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 12; n= 63, 65	-0.364 10^9 cells/L	Standard Deviation 0.8407
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Monocytes; Week 12; n= 63, 65	-0.004 10^9 cells/L	Standard Deviation 0.1985
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 16; n= 64, 68	-0.355 10^9 cells/L	Standard Deviation 0.828
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 56; n= 59, 61	-1.0 10^9 cells/L	Standard Deviation 48.51
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 20; n= 61, 66	-0.347 10^9 cells/L	Standard Deviation 0.8266
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 12; n= 63, 65	-0.071 10^9 cells/L	Standard Deviation 0.7665
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Eosinophils; Week 24; n= 61, 66	-0.364 10^9 cells/L	Standard Deviation 0.8211
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 40; n= 61, 65	-1.010 10^9 cells/L	Standard Deviation 3.3999
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 60; n= 59, 64	-2.0 10^9 cells/L	Standard Deviation 41.32
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 44; n= 59, 61	-1.344 10^9 cells/L	Standard Deviation 2.1031
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 12; n= 63, 65	-1.24 10^9 cells/L	Standard Deviation 2.716
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 48; n= 59, 64	-1.151 10^9 cells/L	Standard Deviation 2.5806
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 48; n=59, 64	0.035 10^9 cells/L	Standard Deviation 0.7368
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 52; n= 60, 64	-1.211 10^9 cells/L	Standard Deviation 2.2815
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; ; Week 16; n= 64, 68	-1.16 10^9 cells/L	Standard Deviation 2.827
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 56; n= 59, 61	-1.311 10^9 cells/L	Standard Deviation 3.0024
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 16; n= 64, 68	0.079 10^9 cells/L	Standard Deviation 0.7254
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Neutrophils; Week 60; n= 58, 64	-0.795 10^9 cells/L	Standard Deviation 2.6501
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 20; n= 61, 66	-1.43 10^9 cells/L	Standard Deviation 2.649
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Platelets; Baseline; n= 68, 68	270.3 10^9 cells/L	Standard Deviation 60.86
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Absolute Monocytes; Baseline; n= 68, 68	0.405 10^9 cells/L	Standard Deviation 0.2376
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 4; n= 66, 67	-1.4 10^9 cells/L	Standard Deviation 33.79
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 24; n= 61, 66	-1.47 10^9 cells/L	Standard Deviation 2.738
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 8; n= 66, 66	4.1 10^9 cells/L	Standard Deviation 26.48
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Lymphocytes; Week 20; n= 61, 66	0.127 10^9 cells/L	Standard Deviation 0.7096
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 12; n= 63, 65	-4.3 10^9 cells/L	Standard Deviation 37.89
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Leukocytes; Week 28; n= 62, 65	-1.66 10^9 cells/L	Standard Deviation 2.804
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels	Platelets; Week 16; n= 64, 68	1.8 10^9 cells/L	Standard Deviation 40.25

Secondary

Change From Baseline in Hematology Parameters of Erythrocytes Levels

Blood samples were collected to evaluate change from Baseline in erythrocytes values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Absolute, Baseline; n= 68, 68	4.64 10^12 cells/L	Standard Deviation 0.511
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 4; n= 66, 67	-0.07 10^12 cells/L	Standard Deviation 0.228
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 8; n= 66, 66	-0.07 10^12 cells/L	Standard Deviation 0.278
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 12; n= 63, 65	-0.04 10^12 cells/L	Standard Deviation 0.273
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 16; n= 64, 68	-0.02 10^12 cells/L	Standard Deviation 0.266
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 20; n= 61, 68	0.03 10^12 cells/L	Standard Deviation 0.243
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 24; n= 62, 66	0.02 10^12 cells/L	Standard Deviation 0.252
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 28; n= 62, 66	0.03 10^12 cells/L	Standard Deviation 0.286
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 32; n= 61, 67	0.06 10^12 cells/L	Standard Deviation 0.3
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 36; n= 60, 66	0.08 10^12 cells/L	Standard Deviation 0.314
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 40; n= 61, 65	0.09 10^12 cells/L	Standard Deviation 0.274
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 44; n= 60, 64	0.13 10^12 cells/L	Standard Deviation 0.332
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 48; n= 59, 64	0.14 10^12 cells/L	Standard Deviation 0.293
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 52; n= 60, 64	0.10 10^12 cells/L	Standard Deviation 0.309
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 56; n= 59, 61	0.06 10^12 cells/L	Standard Deviation 0.365
Placebo	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 60; n= 59, 64	0.07 10^12 cells/L	Standard Deviation 0.384
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 60; n= 59, 64	0.05 10^12 cells/L	Standard Deviation 0.318
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Absolute, Baseline; n= 68, 68	4.58 10^12 cells/L	Standard Deviation 0.456
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 32; n= 61, 67	0.09 10^12 cells/L	Standard Deviation 0.273
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 4; n= 66, 67	-0.03 10^12 cells/L	Standard Deviation 0.226
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 48; n= 59, 64	0.10 10^12 cells/L	Standard Deviation 0.271
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 8; n= 66, 66	-0.01 10^12 cells/L	Standard Deviation 0.211
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 36; n= 60, 66	0.14 10^12 cells/L	Standard Deviation 0.299
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 12; n= 63, 65	-0.04 10^12 cells/L	Standard Deviation 0.252
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 56; n= 59, 61	0.07 10^12 cells/L	Standard Deviation 0.284
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 16; n= 64, 68	-0.01 10^12 cells/L	Standard Deviation 0.243
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 40; n= 61, 65	0.09 10^12 cells/L	Standard Deviation 0.27
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 20; n= 61, 68	0.03 10^12 cells/L	Standard Deviation 0.252
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 52; n= 60, 64	0.09 10^12 cells/L	Standard Deviation 0.251
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 24; n= 62, 66	0.05 10^12 cells/L	Standard Deviation 0.265
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 44; n= 60, 64	0.08 10^12 cells/L	Standard Deviation 0.26
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Erythrocytes Levels	Week 28; n= 62, 66	0.08 10^12 cells/L	Standard Deviation 0.264

Secondary

Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels

Blood samples were collected to evaluate change from Baseline in MCHC and hemoglobin values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 32; n= 61, 67	-6.6 g/L	Standard Deviation 8.19
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 4; n= 66, 67	-1.2 g/L	Standard Deviation 6.02
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 8; n= 66, 66	-1.5 g/L	Standard Deviation 6.69
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 12; n= 63, 65	-1.3 g/L	Standard Deviation 7.73
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 16; n= 64, 68	-2.3 g/L	Standard Deviation 7.11
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 20; n= 61, 68	-2.2 g/L	Standard Deviation 6.65
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 24; n= 62, 66	-3.2 g/L	Standard Deviation 10.19
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 28; n= 62, 66	-4.3 g/L	Standard Deviation 7.07
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Absolute MCHC; Baseline; n= 68, 68	324.9 g/L	Standard Deviation 7.53
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 36; n= 60, 66	-4.7 g/L	Standard Deviation 8.05
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 40; n= 61, 65	-4.5 g/L	Standard Deviation 8.04
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 44; n= 60, 64	-4.7 g/L	Standard Deviation 8.51
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 48; n= 59, 64	-6.0 g/L	Standard Deviation 8.03
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 52; n= 60, 64	-5.2 g/L	Standard Deviation 7.79
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 60; n= 59, 64	-1.8 g/L	Standard Deviation 9.86
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 56; n= 59, 61	-6.9 g/L	Standard Deviation 7.74
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 60; n= 59, 64	-7.5 g/L	Standard Deviation 7.41
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Absolute Hemoglobin; Baseline; n= 68, 68	141.6 g/L	Standard Deviation 12.67
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 4; n= 66, 67	-2.3 g/L	Standard Deviation 6.86
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 28; n= 62, 66	-1.3 g/L	Standard Deviation 7.48
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 32; n= 61, 67	-1.3 g/L	Standard Deviation 8.03
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 36; n= 60, 66	-0.2 g/L	Standard Deviation 8.5
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 40; n= 61, 65	0.1 g/L	Standard Deviation 8.35
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 44; n= 60, 64	0.7 g/L	Standard Deviation 9.59
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 48; n= 59, 64	0.5 g/L	Standard Deviation 8.2
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 52; n= 60, 64	0.1 g/L	Standard Deviation 8.57
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 8; n= 66, 66	-2.5 g/L	Standard Deviation 7.56
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 12; n= 63, 65	-1.6 g/L	Standard Deviation 8.28
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 16; n= 64, 68	-1.6 g/L	Standard Deviation 8.24
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 20; n= 61, 68	-0.3 g/L	Standard Deviation 6.85
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 24; n= 62, 66	-1.1 g/L	Standard Deviation 8.06
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 56; n= 59, 61	-1.5 g/L	Standard Deviation 9.92
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 60; n= 59, 64	-4.7 g/L	Standard Deviation 9.9
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Absolute MCHC; Baseline; n= 68, 68	324.4 g/L	Standard Deviation 7.37
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 48; n= 59, 64	-1.9 g/L	Standard Deviation 11.07
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 4; n= 66, 67	-1.1 g/L	Standard Deviation 5.92
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Absolute Hemoglobin; Baseline; n= 68, 68	140.6 g/L	Standard Deviation 12.99
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 8; n= 66, 66	-1.5 g/L	Standard Deviation 6.86
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 20; n= 61, 68	-1.4 g/L	Standard Deviation 7.64
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 12; n= 63, 65	0.3 g/L	Standard Deviation 6.6
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 60; n= 59, 64	-2.4 g/L	Standard Deviation 11.36
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 16; n= 64, 68	-2.1 g/L	Standard Deviation 7.88
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 24; n= 62, 66	-1.6 g/L	Standard Deviation 8.51
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 20; n= 61, 68	-1.2 g/L	Standard Deviation 7.88
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 52; n= 60, 64	-1.9 g/L	Standard Deviation 10.36
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 24; n= 62, 66	-2.6 g/L	Standard Deviation 7.39
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 28; n= 62, 66	-1.3 g/L	Standard Deviation 8.94
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 28; n= 62, 66	-2.6 g/L	Standard Deviation 7.33
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 4; n= 66, 67	-1.8 g/L	Standard Deviation 6.43
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 32; n= 61, 67	-3.6 g/L	Standard Deviation 7.56
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 32; n= 61, 67	-1.6 g/L	Standard Deviation 9.22
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 36; n= 60, 66	-3.3 g/L	Standard Deviation 8.37
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 16; n= 64, 68	-1.9 g/L	Standard Deviation 7.64
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 40; n= 61, 65	-3.2 g/L	Standard Deviation 8.96
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 36; n= 60, 66	-0.4 g/L	Standard Deviation 10.23
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 44; n= 60, 64	-4.5 g/L	Standard Deviation 9.4
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 8; n= 66, 66	-1.1 g/L	Standard Deviation 6.28
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 48; n= 59, 64	-4.8 g/L	Standard Deviation 10.56
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 40; n= 61, 65	-0.9 g/L	Standard Deviation 9.74
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 56; n= 59, 61	-1.9 g/L	Standard Deviation 11.48
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 52; n= 60, 64	-5.3 g/L	Standard Deviation 7.72
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 44; n= 60, 64	-1.9 g/L	Standard Deviation 10.47
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	MCHC; Week 56; n= 59, 61	-5.3 g/L	Standard Deviation 7.47
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels	Hemoglobin; Week 12; n= 63, 65	-2.2 g/L	Standard Deviation 7.17

Secondary

Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels

Blood samples were collected to evaluate change from Baseline in MCH values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Absolute, Baseline; n= 68, 68	30.77 Picogram (pg)	Standard Deviation 2.902
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 4; n= 66, 67	0.04 Picogram (pg)	Standard Deviation 0.331
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 8; n= 66, 66	-0.02 Picogram (pg)	Standard Deviation 0.95
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 12; n= 63, 65	-0.04 Picogram (pg)	Standard Deviation 0.55
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 16; n= 64, 68	-0.21 Picogram (pg)	Standard Deviation 0.845
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 20; n= 61, 68	-0.28 Picogram (pg)	Standard Deviation 0.665
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 24; n= 62, 66	-0.45 Picogram (pg)	Standard Deviation 1.27
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 28; n= 62, 66	-0.51 Picogram (pg)	Standard Deviation 0.618
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 32; n= 61, 67	-0.66 Picogram (pg)	Standard Deviation 0.764
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 36; n= 60, 66	-0.60 Picogram (pg)	Standard Deviation 0.91
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 40; n= 61, 65	-0.67 Picogram (pg)	Standard Deviation 1.171
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 44; n= 60, 64	-0.78 Picogram (pg)	Standard Deviation 1.566
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 48; n= 59, 64	-0.87 Picogram (pg)	Standard Deviation 1.745
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 52; n= 60, 64	-0.69 Picogram (pg)	Standard Deviation 1.908
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 56; n= 59, 61	-0.79 Picogram (pg)	Standard Deviation 2.056
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 60; n= 59, 64	-0.86 Picogram (pg)	Standard Deviation 2.094
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 60; n= 59, 64	-0.80 Picogram (pg)	Standard Deviation 1.818
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Absolute, Baseline; n= 68, 68	30.77 Picogram (pg)	Standard Deviation 2.255
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 32; n= 61, 67	-0.88 Picogram (pg)	Standard Deviation 1.368
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 4; n= 66, 67	-0.12 Picogram (pg)	Standard Deviation 0.785
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 48; n= 59, 64	-0.96 Picogram (pg)	Standard Deviation 1.654
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 8; n= 66, 66	-0.16 Picogram (pg)	Standard Deviation 0.653
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 36; n= 60, 66	-0.90 Picogram (pg)	Standard Deviation 1.395
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 12; n= 63, 65	-0.17 Picogram (pg)	Standard Deviation 0.769
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 56; n= 59, 61	-0.83 Picogram (pg)	Standard Deviation 1.713
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 16; n= 64, 68	-0.34 Picogram (pg)	Standard Deviation 0.769
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 40; n= 61, 65	-0.79 Picogram (pg)	Standard Deviation 1.39
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 20; n= 61, 68	-0.41 Picogram (pg)	Standard Deviation 0.851
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 52; n= 60, 64	-0.95 Picogram (pg)	Standard Deviation 1.585
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 24; n= 62, 66	-0.59 Picogram (pg)	Standard Deviation 0.959
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 44; n= 60, 64	-0.95 Picogram (pg)	Standard Deviation 1.484
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels	Week 28; n= 62, 66	-0.70 Picogram (pg)	Standard Deviation 1.184

Secondary

Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels

Blood samples were collected to evaluate change from Baseline in MCV values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Absolute, Baseline; n= 68, 68	94.8 femtoliter (fL)	Standard Deviation 9.02
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 4; n= 66, 67	0.4 femtoliter (fL)	Standard Deviation 1.67
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 8; n= 66, 66	0.3 femtoliter (fL)	Standard Deviation 2.5
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 12; n= 63, 65	0.2 femtoliter (fL)	Standard Deviation 2
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 16; n= 64, 68	0.0 femtoliter (fL)	Standard Deviation 2.22
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 20; n= 61, 68	-0.3 femtoliter (fL)	Standard Deviation 1.87
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 24; n= 62, 66	-0.5 femtoliter (fL)	Standard Deviation 2.21
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 28; n= 62, 66	-0.4 femtoliter (fL)	Standard Deviation 2.86
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 32; n= 61, 67	-0.2 femtoliter (fL)	Standard Deviation 3.01
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 36; n= 60, 66	-0.5 femtoliter (fL)	Standard Deviation 3.55
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 40; n= 61, 65	-0.9 femtoliter (fL)	Standard Deviation 4.09
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 44; n= 60, 64	-1.2 femtoliter (fL)	Standard Deviation 5.06
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 48; n= 59, 64	-1.1 femtoliter (fL)	Standard Deviation 5.96
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 52; n= 60, 64	-0.8 femtoliter (fL)	Standard Deviation 6.52
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 56; n= 59, 61	-0.5 femtoliter (fL)	Standard Deviation 6.47
Placebo	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 60; n= 59, 64	-0.6 femtoliter (fL)	Standard Deviation 6.57
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 60; n= 59, 64	-1.0 femtoliter (fL)	Standard Deviation 4.49
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Absolute, Baseline; n= 68, 68	94.8 femtoliter (fL)	Standard Deviation 6.14
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 32; n= 61, 67	-1.7 femtoliter (fL)	Standard Deviation 3.56
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 4; n= 66, 67	0.0 femtoliter (fL)	Standard Deviation 2.33
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 48; n= 59, 64	-1.5 femtoliter (fL)	Standard Deviation 4.04
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 8; n= 66, 66	0.0 femtoliter (fL)	Standard Deviation 2.58
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 36; n= 60, 66	-1.9 femtoliter (fL)	Standard Deviation 3.74
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 12; n= 63, 65	-0.7 femtoliter (fL)	Standard Deviation 2.3
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 56; n= 59, 61	-1.0 femtoliter (fL)	Standard Deviation 4.15
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 16; n= 64, 68	-0.4 femtoliter (fL)	Standard Deviation 2.94
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 40; n= 61, 65	-1.4 femtoliter (fL)	Standard Deviation 3.73
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 20; n= 61, 68	-0.9 femtoliter (fL)	Standard Deviation 2.66
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 52; n= 60, 64	-1.3 femtoliter (fL)	Standard Deviation 4.29
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 24; n= 62, 66	-1.0 femtoliter (fL)	Standard Deviation 2.92
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 44; n= 60, 64	-1.5 femtoliter (fL)	Standard Deviation 3.91
Mepolizumab 300mg	Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels	Week 28; n= 62, 66	-1.4 femtoliter (fL)	Standard Deviation 3.48

Secondary

Change From Baseline in Pulse Rate

Pulse rate was measured from Baseline throughout follow-up (till Week 60) before injection with the participant sitting, having rested in this position for at least 5 minutes before reading. The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Pulse Rate	Week 8; n= 67, 68	0.97 beats per minute (bpm)	Standard Deviation 10.718
Placebo	Change From Baseline in Pulse Rate	Absolute Baseline; n= 68, 68	77.38 beats per minute (bpm)	Standard Deviation 13.763
Placebo	Change From Baseline in Pulse Rate	Week 4; n= 68, 68	2.01 beats per minute (bpm)	Standard Deviation 12.294
Placebo	Change From Baseline in Pulse Rate	Week 12; n= 66, 68	1.52 beats per minute (bpm)	Standard Deviation 12.393
Placebo	Change From Baseline in Pulse Rate	Week 16; n= 64, 68	0.59 beats per minute (bpm)	Standard Deviation 11.287
Placebo	Change From Baseline in Pulse Rate	Week 20; n= 63, 68	1.03 beats per minute (bpm)	Standard Deviation 11.521
Placebo	Change From Baseline in Pulse Rate	Week 24; n= 63, 67	0.79 beats per minute (bpm)	Standard Deviation 12.134
Placebo	Change From Baseline in Pulse Rate	Week 28; n= 62, 67	1.29 beats per minute (bpm)	Standard Deviation 10.439
Placebo	Change From Baseline in Pulse Rate	Week 32; n= 62, 67	1.60 beats per minute (bpm)	Standard Deviation 11.703
Placebo	Change From Baseline in Pulse Rate	Week 36; n= 62, 67	3.47 beats per minute (bpm)	Standard Deviation 12.538
Placebo	Change From Baseline in Pulse Rate	Week 40; n= 62, 66	2.65 beats per minute (bpm)	Standard Deviation 12.297
Placebo	Change From Baseline in Pulse Rate	Week 44; n= 61, 66	3.10 beats per minute (bpm)	Standard Deviation 12.195
Placebo	Change From Baseline in Pulse Rate	Week 48; n= 61, 65	3.85 beats per minute (bpm)	Standard Deviation 12.383
Placebo	Change From Baseline in Pulse Rate	Week 52; n= 61, 65	1.85 beats per minute (bpm)	Standard Deviation 11.987
Placebo	Change From Baseline in Pulse Rate	Week 56; n= 62, 63	2.60 beats per minute (bpm)	Standard Deviation 14.041
Placebo	Change From Baseline in Pulse Rate	Week 60; n= 61, 65	1.51 beats per minute (bpm)	Standard Deviation 12.793
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 60; n= 61, 65	0.09 beats per minute (bpm)	Standard Deviation 10.28
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 32; n= 62, 67	-0.31 beats per minute (bpm)	Standard Deviation 10.53
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Absolute Baseline; n= 68, 68	75.75 beats per minute (bpm)	Standard Deviation 10.404
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 48; n= 61, 65	-1.12 beats per minute (bpm)	Standard Deviation 10.315
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 4; n= 68, 68	1.87 beats per minute (bpm)	Standard Deviation 10.543
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 8; n= 67, 68	-1.01 beats per minute (bpm)	Standard Deviation 10.304
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 36; n= 62, 67	-0.57 beats per minute (bpm)	Standard Deviation 11.422
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 12; n= 66, 68	-0.12 beats per minute (bpm)	Standard Deviation 10.855
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 56; n= 62, 63	-0.35 beats per minute (bpm)	Standard Deviation 9.986
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 16; n= 64, 68	0.44 beats per minute (bpm)	Standard Deviation 11.411
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 40; n= 62, 66	0.74 beats per minute (bpm)	Standard Deviation 11.669
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 20; n= 63, 68	-0.56 beats per minute (bpm)	Standard Deviation 9.687
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 52; n= 61, 65	-2.17 beats per minute (bpm)	Standard Deviation 9.596
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 24; n= 63, 67	0.37 beats per minute (bpm)	Standard Deviation 10.057
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 44; n= 61, 66	0.15 beats per minute (bpm)	Standard Deviation 12.763
Mepolizumab 300mg	Change From Baseline in Pulse Rate	Week 28; n= 62, 67	0.16 beats per minute (bpm)	Standard Deviation 10.093

Secondary

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels

SBP and DBP were measured from Baseline throughout follow-up (till Week 60) before injection with the participant sitting, having rested in this position for at least 5 minutes before reading. The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Time frame: Baseline up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 32; n= 62, 67	-2.35 millimeter of mercury (mm of Hg)	Standard Deviation 14.027
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 4; n= 68, 68	0.47 millimeter of mercury (mm of Hg)	Standard Deviation 15.865
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 8; n= 67, 68	0.07 millimeter of mercury (mm of Hg)	Standard Deviation 14.192
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 12; n= 66, 68	-1.12 millimeter of mercury (mm of Hg)	Standard Deviation 14.38
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 16; n= 64, 68	-0.97 millimeter of mercury (mm of Hg)	Standard Deviation 16.63
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 20; n= 63, 68	-0.97 millimeter of mercury (mm of Hg)	Standard Deviation 15.028
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 24; n= 63, 67	-1.54 millimeter of mercury (mm of Hg)	Standard Deviation 15.449
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 28; n= 63, 67	-0.06 millimeter of mercury (mm of Hg)	Standard Deviation 14.337
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	Absolute SBP; Baseline; n= 68, 68	127.46 millimeter of mercury (mm of Hg)	Standard Deviation 17.794
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 36; n= 62, 67	1.02 millimeter of mercury (mm of Hg)	Standard Deviation 14.663
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 40; n= 62, 66	0.90 millimeter of mercury (mm of Hg)	Standard Deviation 14.202
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 44; n= 61, 66	1.41 millimeter of mercury (mm of Hg)	Standard Deviation 16.143
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 48; n= 61, 65	-0.41 millimeter of mercury (mm of Hg)	Standard Deviation 17.14
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP: Week 52; n= 61, 65	-1.03 millimeter of mercury (mm of Hg)	Standard Deviation 13.2
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 56; n= 62, 63	0.06 millimeter of mercury (mm of Hg)	Standard Deviation 15.216
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 60; n= 61, 65	0.61 millimeter of mercury (mm of Hg)	Standard Deviation 15.627
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	Absolute DBP; Baseline; n= 68, 68	80.21 millimeter of mercury (mm of Hg)	Standard Deviation 10.127
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 4; n= 68, 68	-2.26 millimeter of mercury (mm of Hg)	Standard Deviation 10.046
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 8; n= 67, 68	-2.04 millimeter of mercury (mm of Hg)	Standard Deviation 8.461
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 12; n= 66, 68	-1.92 millimeter of mercury (mm of Hg)	Standard Deviation 10.115
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 16; n= 64, 68	-1.36 millimeter of mercury (mm of Hg)	Standard Deviation 10.237
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 20; n= 63, 68	-1.25 millimeter of mercury (mm of Hg)	Standard Deviation 8.092
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 24; n= 63, 67	-2.24 millimeter of mercury (mm of Hg)	Standard Deviation 8.751
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 28; n= 63, 67	-2.02 millimeter of mercury (mm of Hg)	Standard Deviation 9.939
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 32; n= 62, 67	-4.27 millimeter of mercury (mm of Hg)	Standard Deviation 9.313
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 36; n= 62, 67	-1.97 millimeter of mercury (mm of Hg)	Standard Deviation 10.995
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 40; n= 62, 66	-0.48 millimeter of mercury (mm of Hg)	Standard Deviation 9.625
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 44; n= 61, 66	-0.79 millimeter of mercury (mm of Hg)	Standard Deviation 9.93
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 48; n= 61, 65	-3.26 millimeter of mercury (mm of Hg)	Standard Deviation 10.466
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 52; n= 61, 65	-3.66 millimeter of mercury (mm of Hg)	Standard Deviation 10.628
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 56; n= 62, 63	-3.48 millimeter of mercury (mm of Hg)	Standard Deviation 10.57
Placebo	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 60; n= 61, 65	-2.54 millimeter of mercury (mm of Hg)	Standard Deviation 11.278
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 60; n= 61, 65	-0.45 millimeter of mercury (mm of Hg)	Standard Deviation 9.836
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	Absolute SBP; Baseline; n= 68, 68	122.46 millimeter of mercury (mm of Hg)	Standard Deviation 14.134
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	Absolute DBP; Baseline; n= 68, 68	76.22 millimeter of mercury (mm of Hg)	Standard Deviation 9.646
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 4; n= 68, 68	0.93 millimeter of mercury (mm of Hg)	Standard Deviation 12.37
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 32; n= 62, 67	-0.49 millimeter of mercury (mm of Hg)	Standard Deviation 10.652
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 8; n= 67, 68	1.29 millimeter of mercury (mm of Hg)	Standard Deviation 11.066
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 4; n= 68, 68	1.01 millimeter of mercury (mm of Hg)	Standard Deviation 10.13
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 12; n= 66, 68	-1.41 millimeter of mercury (mm of Hg)	Standard Deviation 12.071
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 48; n= 61, 65	-1.71 millimeter of mercury (mm of Hg)	Standard Deviation 9.239
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 16; n= 64, 68	-0.41 millimeter of mercury (mm of Hg)	Standard Deviation 11.579
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 8; n= 67, 68	-0.34 millimeter of mercury (mm of Hg)	Standard Deviation 10.078
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 20; n= 63, 68	-0.85 millimeter of mercury (mm of Hg)	Standard Deviation 12.019
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 36; n= 62, 67	0.16 millimeter of mercury (mm of Hg)	Standard Deviation 10.988
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 24; n= 63, 67	-1.57 millimeter of mercury (mm of Hg)	Standard Deviation 12.824
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 12; n= 66, 68	-0.37 millimeter of mercury (mm of Hg)	Standard Deviation 9.167
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 28; n= 63, 67	-0.15 millimeter of mercury (mm of Hg)	Standard Deviation 13.24
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 56; n= 62, 63	0.11 millimeter of mercury (mm of Hg)	Standard Deviation 8.899
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 32; n= 62, 67	0.04 millimeter of mercury (mm of Hg)	Standard Deviation 11.181
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 16; n= 64, 68	0.46 millimeter of mercury (mm of Hg)	Standard Deviation 9.824
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 36; n= 62, 67	0.48 millimeter of mercury (mm of Hg)	Standard Deviation 14.397
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 40; n= 62, 66	-0.03 millimeter of mercury (mm of Hg)	Standard Deviation 8.868
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 40; n= 62, 66	1.27 millimeter of mercury (mm of Hg)	Standard Deviation 12.075
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 20; n= 63, 68	-1.19 millimeter of mercury (mm of Hg)	Standard Deviation 9.214
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 44; n= 61, 66	-0.36 millimeter of mercury (mm of Hg)	Standard Deviation 13.694
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 52; n= 61, 65	-0.06 millimeter of mercury (mm of Hg)	Standard Deviation 9.236
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 48; n= 61, 65	-0.22 millimeter of mercury (mm of Hg)	Standard Deviation 12.351
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 24; n= 63, 67	-1.16 millimeter of mercury (mm of Hg)	Standard Deviation 9.629
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP: Week 52; n= 61, 65	-0.32 millimeter of mercury (mm of Hg)	Standard Deviation 13.091
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 44; n= 61, 66	-1.03 millimeter of mercury (mm of Hg)	Standard Deviation 9.595
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 56; n= 62, 63	1.02 millimeter of mercury (mm of Hg)	Standard Deviation 13.559
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	DBP; Week 28; n= 63, 67	0.36 millimeter of mercury (mm of Hg)	Standard Deviation 10.071
Mepolizumab 300mg	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels	SBP; Week 60; n= 61, 65	-0.63 millimeter of mercury (mm of Hg)	Standard Deviation 11.656

Secondary

Maximum Change From Baseline in QTcF and QTcB Values

Single measurements of 12-lead ECGs were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Maximum change from Baseline in QTcF and QTcB values were measured.

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Maximum Change From Baseline in QTcF and QTcB Values	QTcB interval	18.8 msec	Standard Deviation 26.46
Placebo	Maximum Change From Baseline in QTcF and QTcB Values	QTcF interval	16.9 msec	Standard Deviation 23.74
Mepolizumab 300mg	Maximum Change From Baseline in QTcF and QTcB Values	QTcB interval	18.1 msec	Standard Deviation 15.28
Mepolizumab 300mg	Maximum Change From Baseline in QTcF and QTcB Values	QTcF interval	15.4 msec	Standard Deviation 13.79

Secondary

Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values

Single measurements of 12-lead electrocardiogram (ECGs) were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Mean change from Baseline in QTcF and QTcB values were measured. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame: Baseline and up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 8; n= 66, 66	0.1 milliseconds (msec)	Standard Deviation 17.9
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 16; n= 64, 66	0.8 milliseconds (msec)	Standard Deviation 15.26
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 24; n= 60, 66	2.8 milliseconds (msec)	Standard Deviation 14.43
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 32; n= 61, 66	6.2 milliseconds (msec)	Standard Deviation 25.19
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 40; n= 61, 65	-0.5 milliseconds (msec)	Standard Deviation 15.25
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 52; n= 58, 64	2.0 milliseconds (msec)	Standard Deviation 15.96
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 60; n= 58, 63	3.0 milliseconds (msec)	Standard Deviation 14.3
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Any time post Baseline; n= 68, 68	16.9 milliseconds (msec)	Standard Deviation 23.74
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 8; n= 66, 66	-0.8 milliseconds (msec)	Standard Deviation 19.05
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 16; n= 64, 66	-0.1 milliseconds (msec)	Standard Deviation 18.33
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 24; n= 60, 66	1.4 milliseconds (msec)	Standard Deviation 17.89
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 32; n= 61, 66	5.2 milliseconds (msec)	Standard Deviation 29.63
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 40; n= 61, 65	-0.6 milliseconds (msec)	Standard Deviation 17.83
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 52; n= 58, 64	1.8 milliseconds (msec)	Standard Deviation 17.64
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 60; n= 58, 63	1.2 milliseconds (msec)	Standard Deviation 16.56
Placebo	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Any time post Baseline; n= 68, 68	18.8 milliseconds (msec)	Standard Deviation 26.46
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Any time post Baseline; n= 68, 68	18.1 milliseconds (msec)	Standard Deviation 15.28
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 8; n= 66, 66	1.0 milliseconds (msec)	Standard Deviation 15.03
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 8; n= 66, 66	0.9 milliseconds (msec)	Standard Deviation 17.31
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 16; n= 64, 66	0.2 milliseconds (msec)	Standard Deviation 14.05
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 40; n= 61, 65	-1.4 milliseconds (msec)	Standard Deviation 18.88
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 24; n= 60, 66	1.9 milliseconds (msec)	Standard Deviation 16.66
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 16; n= 64, 66	-0.9 milliseconds (msec)	Standard Deviation 14.76
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 32; n= 61, 66	1.5 milliseconds (msec)	Standard Deviation 17.16
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 60; n= 58, 63	2.7 milliseconds (msec)	Standard Deviation 17.27
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 40; n= 61, 65	-0.3 milliseconds (msec)	Standard Deviation 17.53
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 24; n= 60, 66	1.0 milliseconds (msec)	Standard Deviation 18.1
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 52; n= 58, 64	3.0 milliseconds (msec)	Standard Deviation 16.04
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 52; n= 58, 64	0.7 milliseconds (msec)	Standard Deviation 18.27
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Week 60; n= 58, 63	2.9 milliseconds (msec)	Standard Deviation 14.97
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcB; Week 32; n= 61, 66	0.0 milliseconds (msec)	Standard Deviation 19.63
Mepolizumab 300mg	Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values	QTcF; Any time post Baseline; n= 68, 68	15.4 milliseconds (msec)	Standard Deviation 13.79

Secondary

Number of Participants in Each Category of Accrued Duration of Remission

Total accrued duration of remission, i.e., the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose \<=7.5mg/day over the 52 week study treatment period was reported. BVAS is a validated, clinician-completed tool used for the comprehensive multisystem clinical assessment of disease activity in systemic vasculitis. The duration was categorized into zero, \>0 to \<12 weeks, 12 to \<24 weeks, 24 to \<36 weeks and \>=36 weeks. Statistical analysis was performed on ITT Population and was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Time frame: Up to Week 52

Population: ITT Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	>0 to <12 weeks	19 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	24 to <36 weeks	7 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	12 to <24 weeks	0 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	>=36 weeks	6 Participants
Placebo	Number of Participants in Each Category of Accrued Duration of Remission	Zero	36 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	>=36 weeks	22 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	Zero	15 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	>0 to <12 weeks	15 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	12 to <24 weeks	7 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Accrued Duration of Remission	24 to <36 weeks	9 Participants

p-value: <0.00195% CI: [2.63, 10.74]Proportional odds regression model

Secondary

Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.

The number of participants with an average daily prednisolone/prednisone dose during the last 4 weeks of the Study Treatment Period (48 through 52) was calculated. The average dose was categorized into zero, \>0 to \<=4.0mg, \>4.0 to \<=7.5mg and \>7.5mg. The statistical analysis was performed using a proportional odds regression model with Baseline covariates of treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region and the comparison between treatment groups was presented as an odds ratio, p-value and 95 percent CI.

Time frame: Week 48 and Week52

Population: ITT Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Placebo	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	Zero	2 Participants
Placebo	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	>0 to <=4.0mg	3 Participants
Placebo	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	>4.0 to <=7.5mg	18 Participants
Placebo	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	>7.5mg	45 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	>7.5mg	28 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	Zero	12 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	>4.0 to <=7.5mg	10 Participants
Mepolizumab 300mg	Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.	>0 to <=4.0mg	18 Participants

p-value: <0.00195% CI: [0.09, 0.41]Proportional odds regression model

Secondary

Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period

The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone \<=7.5mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Time frame: Up to Week 52

Population: ITT Population

Arm	Measure	Value (NUMBER)
Placebo	Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	2 Participants
Mepolizumab 300mg	Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	16 Participants

p-value: 0.00395% CI: [2.35, 55.24]Regression, Logistic

Secondary

Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period

The number of participants who achieved remission (i.e., BVAS=0 and prednisolone/prednisone\<=4 mg/day) within the first 24 weeks and remain in remission for the remainder of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Time frame: Up to Week 52

Population: ITT Population

Arm	Measure	Value (NUMBER)
Placebo	Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	1 Participants
Mepolizumab 300mg	Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	13 Participants

p-value: 0.00795% CI: [2.3, 167.93]Regression, Logistic

Secondary

Number of Participants Who Are in Remission at 36 and 48 Weeks

Time frame: Week 36 and Week 48

Population: ITT Population

Arm	Measure	Value (NUMBER)
Placebo	Number of Participants Who Are in Remission at 36 and 48 Weeks	7 Participants
Mepolizumab 300mg	Number of Participants Who Are in Remission at 36 and 48 Weeks	28 Participants

p-value: <0.00195% CI: [2.6, 19.87]Regression, Logistic

Secondary

Number of Participants With Anti-Mepolizumab Antibodies

Blood samples were collected for the determination of anti-Mepolizumab antibodies. Participants who showed presence of anti-Mepolizumab antibody were termed as 'positive' and those who did not have anti-Mepolizumab antibody in blood sample were termed as 'negative'. Participants who did not have a positive ADA assay prior to the first dose of investigational product were included in the analysis.

Time frame: Up to Week 60

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
Placebo	Number of Participants With Anti-Mepolizumab Antibodies	Negative	66 Participants
Placebo	Number of Participants With Anti-Mepolizumab Antibodies	Positive	1 Participants
Mepolizumab 300mg	Number of Participants With Anti-Mepolizumab Antibodies	Negative	65 Participants
Mepolizumab 300mg	Number of Participants With Anti-Mepolizumab Antibodies	Positive	1 Participants

Secondary

Number of Participants With Local and Systemic Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs including systemic allergic and non-allergic reactions as well as local site injection-related reactions were counted throughout treatment phase and follow up phase. Systemic allergic reactions included Facial paralysis, flushing, hypersensitivity and rash pruritic. Injection related reactions were considered as systemic non-allergic reactions. Local site reactions included injection site bruising, erythema, pain and reaction. The analysis was performed on Safety Population which comprised of all participants who receive at least one dose of study treatment.

Time frame: Up to Week 52

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Flushing	0 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site bruising	0 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Rash pruritic	0 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site erythema	1 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Hypersensitivity	0 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site pain	1 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection related reactions	0 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site reaction	7 Participants
Placebo	Number of Participants With Local and Systemic Adverse Events (AEs)	Facial paralysis	1 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site reaction	9 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Facial paralysis	0 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Flushing	1 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Hypersensitivity	1 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Rash pruritic	1 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection related reactions	1 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site bruising	1 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site erythema	1 Participants
Mepolizumab 300mg	Number of Participants With Local and Systemic Adverse Events (AEs)	Injection site pain	0 Participants

Secondary

Time to First EGPA Relapse

EGPA relapse was defined as worsening or persistence of active disease since the last visit characterized by active vasculitis or active asthma symptoms and/or signs with a corresponding worsening in Asthma Control Questionnaire-6 (ACQ-6) score or active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions warranting: i) an increased dose of OCS therapy (or other systemic corticosteroid therapy) to \>4 mg/day prednisolone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalization related to EGPA worsening. Participants who completed study, or withdrawn prematurely from the study without experiencing the event were censored. The number of participants with at least one EGPA relapse during the planned study treatment period are presented.

Time frame: Up to Week 52

Population: ITT Population

Arm	Measure	Value (NUMBER)
Placebo	Time to First EGPA Relapse	56 Participants
Mepolizumab 300mg	Time to First EGPA Relapse	38 Participants

p-value: <0.00195% CI: [0.206, 0.502]Cox Proportional Hazard regression

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Participants in Each Category of Accrued Duration of Remission

Number of Participants Who Are in Remission at 36 and 48 Weeks

Change From Baseline in Body Temperature

Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels

Change From Baseline in Clinical Chemistry Parameter of Troponin Levels

Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels

Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels

Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels

Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels

Change From Baseline in Hematology Parameters of Erythrocytes Levels

Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels

Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels

Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels

Change From Baseline in Pulse Rate

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels

Maximum Change From Baseline in QTcF and QTcB Values

Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values

Number of Participants in Each Category of Accrued Duration of Remission

Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.

Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period

Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period

Number of Participants Who Are in Remission at 36 and 48 Weeks

Number of Participants With Anti-Mepolizumab Antibodies

Number of Participants With Local and Systemic Adverse Events (AEs)

Time to First EGPA Relapse